Document:

EX-10.4

 Exhibit 10.4 

Confidential Treatment Requested 

SUPPLY AGREEMENT 
 This
SUPPLY AGREEMENT (the “Agreement”), effective the          day of
                    , 2016 (the “Effective Date”) is between Greatbatch Ltd., located at 10000 Wehrle Drive, Clarence,
New York 14031, (“Greatbatch”) and QiG Group, LLC, a Delaware limited liability company, located at 5700 Granite Parkway, Suite 960, Plano, Texas, 75024 (“QiG Group”). Greatbatch and QiG Group are referred to
collectively as the “Parties” and individually as a “Party”. 
 RECITALS: 

WHEREAS, QiG Group desires to purchase the Relevant Project Components (as defined below) exclusively from Greatbatch; 

WHEREAS, Greatbatch is in the business of supplying Relevant Project Components; and 

WHEREAS, the Parties desire to terminate, replace and supersede the Umbrella Agreement between Greatbatch and QiG Group, dated
                     and hereby establish the new terms and conditions that shall apply to QiG Group’s exclusive purchase of Relevant
Project Components from Greatbatch. 
 NOW, THEREFORE, in consideration of the mutual covenants contained herein, Greatbatch and QiG Group
hereby agree as follows: 
  

	I.	DEFINITIONS 

 As used in this Agreement, the following capitalized terms, whether used
in the singular or plural, shall have the meanings set forth in this Article I: 
  

	A.	“Acknowledged Order” has the meaning set forth in Section VIII.A. 

  

	B.	“Affiliate” means, with respect to any Person, any other Person which controls, is controlled by or is under common control with such Person. A Person shall be deemed to control another Person if such
Person possesses, directly or indirectly, the power to direct or cause the direction of the management and policies of such Person, whether through the ownership of voting securities, by contract or otherwise. Without limiting the generality of the
foregoing, a Person shall be deemed to control another Person if any of the following conditions is met: (a) in the case of corporate entities, direct or indirect ownership of at least fifty percent (50%) of the stock or shares having the
right to vote for the election of directors, and (b) in the case of non-corporate entities, direct or indirect ownership of at least fifty percent (50%) of the equity interest with the power to 

 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

	 	
direct the management and policies of such non-corporate entities. For purposes of this Agreement, in no event shall QiG Group or any of its Affiliates be deemed Affiliates of Greatbatch (or any
of its Affiliates) nor shall Greatbatch or any of its Affiliates be deemed Affiliates of QiG Group (or any of its Affiliates). 

  

	C.	“Agreement” has the meaning as described in the Preamble. 

  

	D.	“Change of Control” means (i) a consolidation or merger of a Party or other change of control transaction (other than a merger to reincorporate a party in a different jurisdiction) in which the
shareholders or members, as applicable, of a Party immediately prior to such transaction do not continue to hold a greater than 50% interest in the successor or survivor entity immediately following such transaction, (ii) a transaction or
series of transactions that results in the transfer of more than 50% of the voting power of a Party to an unaffiliated Person or (iii) the sale, lease, transfer or other disposition of all or substantially all of the assets of a Party (which
shall include any effective transfer of such assets regardless of the structure of any such transaction as a license or otherwise). 

  

	E.	“Confidential Information” of a Party means any and all information of a confidential or proprietary nature disclosed by a Party under this License Agreement, whether in oral, written, graphic or
electronic format, which includes, but is not limited to, Trade Secrets, discoveries, ideas, concepts, know-how, techniques, designs, specifications, drawings, diagrams, data, business activities and operations, customer lists, reports, studies and
other technical and business information. 

  

	F.	“Consigned Products” has the meaning set forth in Section VIII.A. 

  

	G.	“Consignment Inventory” has the meaning set forth in Section VIII.B. 

  

	H.	“Consignment Orders” has the meaning set forth in Section VIII.A. 

  

	I.	“Exercise Period” has the meaning set forth in Section II.C. 

  

	J.	“Effective Date” has the meaning as described in the Preamble. 

  

	K	“Facility Approval Notice” has the meaning set forth in Section IV.B. 

  

	L.	“FDA” means the U.S. Food & Drug Administration or any successor entity thereto. 

  

	M.	“Field of Use” means spinal cord stimulation. 

  

	N.	“Force Majeure” has the meaning set forth in Section V.N. 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST.
OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 - 2 - 

	O.	“Greatbatch” has the meaning as described in the Preamble. 

  

	P.	“Greatbatch Indemnitees” has the meaning set forth in Section X.C. 

  

	Q.	“Improvements” has the meaning set forth in Section XII.B. 

  

	R.	“Initial Term” has the meaning set forth in Section II.B. 

  

	S.	“Intellectual Property” means all rights held by a Party in its technology, products and business information, all or some of which may constitute Confidential Information, and including but not limited
to: patent rights, copyrights, trademark rights, goodwill, inventions, improvements, discoveries, designs, modifications, data, business information, financial information, clinical information and data, regulatory information, trade secret rights,
mask work, know how rights and other intellectual property and proprietary rights. 

  

	T.	“Joint IP” has the meaning set forth in Section XII.B. 

  

	U.	“Legal Requirements” means any federal, state, local, provincial, foreign, international, multinational or other statute, law, treaty, rule, regulation, guideline, administrative order, directives,
ordinance, constitution or principle of common law (or any interpretation thereof by a governmental entity). 

  

	V.	“Licensed IP” has the meaning set forth in the Restricted License Agreement and the Unrestricted License Agreement. 

 

	W.	“Manufacturing Request” has the meaning set forth in Section II.C. 

  

	Y.	“Person” means an individual, a partnership, a corporation, an association, a joint stock company, a trust, a joint venture, an unincorporated organization, or a governmental entity (or any department,
agency, or political subdivision thereof). 

  

	Z.	“Product” means QiG Group’s Algovita spinal cord stimulation system and its related parts and components that are based on, use or incorporate the Licensed IP (the “Algovita System”) and
such other products, parts and components, including replacement parts and components, that may be incorporated within, used in conjunction with or sold as part of the Algovita System as may be mutually agreed upon by the parties from time to time.

  

	AA.	“QiG Group” has the meaning as described in the Preamble. For purposes of this Agreement, unless the context requires otherwise, any reference herein to QiG Group shall mean QiG Group, LLC and each of
its Affiliates. 

  
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION. 

  
 - 3 - 

	BB.	“QiG Group Indemnitees” has the meaning set forth in Section X.D. 

  

	CC.	“Relevant Project Components” means the parts and components for the Product set forth in Appendix A, which may be amended by the Parties from time-to-time in accordance with this Agreement to
incorporate additional Relevant Project Components. 

  

	DD.	“Renewal Term” has the meaning set forth in Section II.B. 

  

	EE.	“Restricted License Agreement” means that certain Restricted License Agreement, dated
                    , 2016, by and between Greatbatch and QiG Group whereby QiG Group has licensed certain of its intellectual property to
Greatbatch. 

  

	FF.	“Restricted Period” has the meaning set forth in Section XI.B(iv). 

  

	GG.	“Resultant Patents” means any rights under United States and foreign patents and patent applications, including, but not limited to, divisions, continuations, continuations-in-part, reissues, and
reexaminations thereof that arise from any Joint IP (as defined below). 

  

	HH.	“ROFR Notice” has the meaning set forth in Section II.C. 

  

	II.	“ROFR Period” has the meaning set forth in Section II.C. 

  

	JJ.	“Safety Stock” has the meaning set forth in Section VII. 

  

	KK.	“Specifications” has the meaning set forth in Section IV.A. 

  

	LL.	“Term” has the meaning set forth in Section II.B. 

  

	MM.	“Third Party Supply Agreement” has the meaning set forth in Section II.C. 

  

	NN.	“Trade Secrets” means trade secrets as they are defined in the Uniform Trade Secrets Act, as amended (UTSA). 

  

	OO.	“Unrestricted License Agreement” means that certain Unrestricted License Agreement, dated
                    , 2016, by and between Greatbatch and QiG Group whereby QiG Group has licensed certain of its intellectual property to
Greatbatch. 

  

	PP.	“Transfer Date” has the meaning set forth in Section VIII.D. 

  

	QQ.	“Validation Documentation” has the meaning set forth in Section IV.B. 

  

	RR.	“Warranty Period” has the meaning set forth in Section X.A(i). 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST.
OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 - 4 - 

	SS.	“WIP” has the meaning set forth in Section III.B. 

  

	II.	SUPPLY AND CONTRACT PERIOD: 

 A.    Sale and Purchase
Obligations. Subject to all of the terms and conditions of this Agreement: 
  

	 	(i)	Greatbatch agrees that during the Term, it shall have the exclusive right to manufacture and sell to QiG Group all Relevant Project Components (as described in or added to Appendix A) that may be ordered by QiG Group in
accordance with the terms of this Agreement; and 

  

	 	(ii)	QiG Group agrees to purchase exclusively from Greatbatch during the Term its requirements for Relevant Project Components to be used by QiG Group in the Products. 

During the Term, if QiG Group desires to have an item manufactured that replaces or is intended to replace a Relevant Project Component and
such item is based on, or that incorporates, Licensed IP and such item falls within the Field of Use, and if Greatbatch elects to be the manufacturer of such item, then such item shall be included as a “Relevant Project Component”
under this Agreement and Appendix A will be amended to include such item. 
 Subject to the immediately preceding paragraph, during the
Term, if QiG Group desires to have an item manufactured that is based on, or that incorporates, Licensed IP and such item falls within the Field of Use, and if Greatbatch elects to be the manufacturer of such item, then QiG Group and Greatbatch each
agree to negotiate exclusively, reasonably and in good faith with each other for up to [***] days regarding the terms of a manufacturing and supply agreement including, but not limited to, pricing, acceptable margins for each party and any other
unique manufacturing or quality requirements related to such item. In the event that the parties are unable to agree on terms within [***] days, QiG Group shall be free to negotiate a manufacturing and supply agreement with any other third party
suppliers for such item. QiG Group agrees that prior to executing any such third party manufacturing and supply agreement, it will notify Greatbatch of the key terms of such manufacturing and supply agreement and will, for a period of at least [***]
days after Greatbatch’s receipt of such terms, give Greatbatch the opportunity to enter into a manufacturing and supply agreement with QiG Group for such item on terms substantially consistent with such third party manufacturing and supply
agreement. 
 During the Term, if QiG Group desires to have an item manufactured that is not based on or does not incorporate any Licensed
IP but QiG Group intends that such item will be 
  
 CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

  
 - 5 - 

 
used within the Field of Use, then QiG Group will be permitted to negotiate a manufacturing and supply agreement with any third party with respect to such item. QiG Group agrees that prior to
executing any such third party manufacturing and supply agreement, it will notify Greatbatch of the key terms of such manufacturing and supply agreement and will, for a period of at least [***] days after Greatbatch’s receipt of such terms,
give Greatbatch the opportunity to enter into a manufacturing and supply agreement with QiG Group on terms substantially consistent with such third party manufacturing and supply agreement. Further, if at the time QiG Group is initially seeking to
have such item manufactured, (a) Greatbatch is unable to manufacture the item so that the item and its manufacture are at least equivalent in terms of technology, quality, ramp-up times, lead times and capacity to manufacture in accordance with
this Agreement, (b) Greatbatch is unable to provide at least equivalent in terms of price to manufacture as an offering made by a third party, or (c) the Parties otherwise agree in writing, QiG Group will be free to enter into or negotiate
with any other third party supplier for the manufacture of such item(s). 
 Notwithstanding Greatbatch’s exclusive right to manufacture
and sell to QiG Group all Relevant Project Components, the parties hereby agree that QiG Group shall have the right to have a third party manufacture the external devices that are currently manufactured by Minnetronix, Inc. and that are listed under
the heading “External Devices” on Appendix A; provided, that in the event that QiG Group elects to have a third party manufacture the external devices, QiG Group shall (i) provide Greatbatch [***] ([***]) months’ written
notice prior to any purchase of such external devices from such third party, (ii) purchase 100% of its requirements for such external devices from a party other than Greatbatch after the completion of the [***] ([***]) month notice period and
Greatbatch shall have no obligation to sell any external devices to QiG Group; and (iii) purchase from Greatbatch, and be responsible for, all finished product, WIP, raw material, components, all Safety Stock held in accordance with Section
VII, all Consignment Products, and any non-cancelable purchase orders outstanding with suppliers related to such external devices. 

B.    Term of Agreement. This Agreement will be in full force and effect from the date of its execution until the
earliest to occur of (i) the fifth anniversary of the date of FDA approval that permits QiG Group to sell the Products in the United States (the “Initial Term”), (ii) termination by the mutual agreement of the Parties, or
(iii) termination in accordance with the following terms of this Agreement. This Agreement shall automatically be renewed after the Initial Term for successive terms of one (1) year each (each a “Renewal Term”) unless
either Party gives written notice of non-renewal or termination not less than three (3) months prior to the expiration of the Initial Term or 
  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST.
OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 - 6 - 

 
any such Renewal Term (the Initial Term and all Renewal Terms being collectively the “Term”). 

C.    Right of First Refusal. During the period beginning one hundred eighty (180) days prior to the
expiration of the Term and ending on the date that is six (6) months after the expiration of the Term (the “ROFR Period”), in the event that QiG Group determines to seek to purchase its requirements for any Relevant Project
Components from a third party (a “Manufacturing Request”), QiG Group shall promptly, and prior to taking any material steps towards engaging any third party with respect to such Manufacturing Request, notify Greatbatch of such
Manufacturing Request (the “ROFR Notice”). During the ninety (90) day period following Greatbatch’s receipt of the ROFR Notice (the “Exercise Period”), (A) QiG Group and Greatbatch shall negotiate
reasonably and in good faith, on an exclusive basis, regarding entry into a definitive manufacturing and supply agreement with respect to such Manufacturing Request and (B) QiG Group shall not initiate any negotiations regarding a definitive
manufacturing and supply agreement with any third party regarding such Manufacturing Request. 
 If Greatbatch and QiG Group do not execute
and deliver a definitive manufacturing and supply agreement prior to the expiration of the Exercise Period, QiG Group shall be free to negotiate a manufacturing and supply agreement with any third party with respect to such Manufacturing Request (a
“Third Party Supply Agreement”) during the [***] ([***]) month period following the expiration of the Exercise Period; provided that QiG Group, prior to execution of any such Third Party Supply Agreement, provides Greatbatch with
the key terms of such Third Party Supply Agreement and offers it, for a period lasting at least [***] ([***]) days after receipt of the Third Party Supply Agreement by Greatbatch, the opportunity to enter into a manufacturing and supply agreement
with QiG Group on terms substantially consistent with such Third Party Supply Agreement before executing such Third Party Supply Agreement. 

For the avoidance of the doubt, the Parties hereby acknowledge that each Manufacturing Request that occurs during the ROFR Period separately
triggers QiG Group’s right of first refusal obligations pursuant to this Section II.C; provided that in the event that this Agreement has been terminated by QiG Group pursuant to Section III.A(i) or Section III.A(ii), Greatbatch’s right of
first refusal under this Section II.C will be void and QiG Group may freely negotiate with any third party to enter into a Third Party Supply Agreement. 
  

	III.	TERMINATION: 

  

	 	A.	Termination. Notwithstanding the provisions of Section II.B above, this Agreement may be terminated in accordance with the following provisions: 

 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 - 7 - 

	 	(i)	Either Party may terminate this Agreement for cause by giving the other Party thirty (30) days’ prior written notice of such termination if the other Party materially breaches or defaults under any of the
material terms or conditions of this Agreement and fails to cure such material breach or default within sixty (60) days after receiving notice thereof. 

  

	 	(ii)	Either Party shall have the right to terminate this Agreement in its entirety if, at any time, (i) the other Party shall file in any court or agency pursuant to any Legal Requirement of any state or country, a
petition in bankruptcy or insolvency or for reorganization or for an arrangement or for the appointment of a receiver or trustee of the Party or of its assets, (ii) if the other Party shall be served with an involuntary petition against it,
filed in any insolvency proceeding, and such petition shall not be dismissed within sixty (60) days after the filing thereof, (iii) if the other Party shall propose or be a party to any dissolution or liquidation, or (iv) if the other
Party shall make an assignment for the benefit of creditors. In the event that this Agreement is terminated or rejected by a Party or its receiver or trustee under applicable bankruptcy or other Legal Requirements due to such Party’s
bankruptcy, then all rights and licenses granted under or pursuant to this Agreement by such Party to the other Party are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code and any similar state or
foreign Legal Requirements, licenses of rights to “intellectual property” as defined under Section 101(52) of the U.S. Bankruptcy Code. The Parties agree that all intellectual property rights licensed hereunder, including, without
limitation, any patents or patent applications in any country of a Party covered by the license grants under this Agreement, are part of the “intellectual property” as defined under Section 101(52) of the Bankruptcy Code subject to
the protections afforded the non-terminating Party under Section 365(n) of the Bankruptcy Code, any similar law or regulation in any other country; or 

  

	 	(iii)	A Party may terminate this Agreement by giving written notice to the other Party if such other Party has given notice as to an event of Force Majeure and such other Party has suspended its performance hereunder for more
than [***] ([***]) consecutive days. 

 Nothing herein shall be construed to allow either Party the right to terminate this
Agreement for any inadvertent error or minor violation of any law or regulation by the other Party; provided that such error or violation does not have a material adverse effect on the other Party. 

 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 - 8 - 

	B.	Effect of Termination. In the event of termination by Greatbatch under Section III.A, QiG Group will be responsible for paying for (i) raw materials and other items subject to existing non-cancellable
purchase orders that cannot otherwise be reasonably used by Greatbatch, (ii) all work-in-process (“WIP”) costs specific to QiG Group custom designs, (iii) all Safety Stock held in accordance with Section VII, and
(iv) all Consignment Products. 

 In the event of termination by QiG Group under Section III.A, QiG Group will be
responsible for paying for (i) all Safety Stock held in accordance with Article VII and (ii) all Consignment Products. Greatbatch agrees to cooperate in good faith to return, in a timely manner, any and all materials, documentation,
tooling, masks, capital and/or other equipment due to QiG Group. Any and all expenses and/or shipping arrangements will be borne or made by the receiving Party. Further, for the avoidance of doubt, the Parties agree that in the event QiG Group
terminates this Agreement under Section III.A(i) or Section III.A(ii), QiG Group will have the right to have the Relevant Product Components manufactured by another third party supplier and all right of first refusal obligations of QiG Group under
this Agreement will be void and not applicable. 
  

	C.	Amendment to Agreement. This Agreement may not be modified, changed or terminated orally. No change, modification, addition, or amendment shall be valid unless in writing indicating an intent to modify this
Agreement and signed by an authorized officer of each Party. 

  

	IV.	SUPPLY 

  

	A.	The Relevant Project Components shall be manufactured in accordance with the specifications attached hereto as Appendix A (the “Specifications”) and in accordance with the terms of the Quality
Agreement between the parties, effective as of September 22, 2015, as may be amended from time to time by the mutual written agreement of the parties (the “Quality Agreement”). 

 

	B.	During the Term, Greatbatch will manufacture the Relevant Project Components at its Plymouth, Minnesota facility and then likely transfer the manufacturing to another Greatbatch facility. If Greatbatch desires to
relocate the manufacturing of the Relevant Project Components to another Greatbatch facility, Greatbatch shall provide written notice to QiG Group at least [***] months prior to Greatbatch’s proposed date of such relocation, and shall provide
such other information reasonably required by QiG Group with respect to such proposed new location. Following the notice, Greatbatch shall deliver to QiG Group a final qualification report and final qualification parts in connection with the
relocation indicating 

  
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION. 

  
 - 9 - 

	 	
Relevant Project Component equivalence at the new location (“Validation Documentation”). Greatbatch shall not ship any Relevant Project Component manufactured at the new facility
until Greatbatch’s receipt of a written notice from QiG Group that it is ready to receive Relevant Project Components manufactured at the new facility (the “Facility Approval Notice”). QiG Group will use best efforts to achieve
all necessary regulatory approvals as soon as possible after QiG Group’s approval of the Validation Documentation. If QiG Group does not issue the Facility Approval Notice within [***] days after all regulatory approvals necessary to
manufacture the Relevant Project Component at the new location have been obtained and Greatbatch has reasonably demonstrated that it can manufacture the Relevant Project Components in accordance with this Agreement at such new location, then all
prices for the Relevant Project Components will automatically increase by [***] percent ([***]%) unless and until QiG Group issues the Facility Approval Notice. QiG Group shall provide reasonable cooperation to Greatbatch in connection with the
qualification of such new facility. Notwithstanding anything in this Agreement to the contrary, QiG Group understands and agrees that the relocation of the manufacturing facility from the Plymouth, Minnesota facility is accounted for in the pricing
in Appendix B, and therefore, no pricing adjustments will be made as result of such relocation. 

  

	V.	PRICE; ORDERS, DELIVERY, PAYMENT, INSPECTION: 

  

	A.	The prices for the Relevant Project Components shall be as set forth in Appendix B of this Agreement and such prices will be fixed for the Initial Term unless otherwise mutually agreed upon by the Parties in
writing, or as may be adjusted in accordance with this Section V, or as may be reduced in accordance with Section V.P below. Notwithstanding anything in this Agreement to the contrary, the price for any Relevant Project Component may be increased
from time-to-time during the Term if Greatbatch’s cost for any individual material or all of the materials used in the manufacture of such Relevant Project Component increases by [***]% or more. If Greatbatch determines that there has been
such a change to its cost, it will provide QiG Group with at least 30 days’ written notice before adjusting the price for such Relevant Project Component; provided, that the change in price shall not exceed the increased cost to Greatbatch.

  

	B.	Simultaneous with the execution of this Agreement, and on each January 1st thereafter, QiG Group will deliver to Greatbatch a blanket purchase order by product
category described on Exhibit B for the Relevant Project Components to be purchased by QiG Group for the remaining calendar year (a “Firm Purchase Order”). 

 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 - 10 - 

	C.	To the extent that the price for a Relevant Project Component is based on a volume pricing table set forth in Appendix B (a “Volume Priced Component”), the price for such Volume Priced Component shall
be based on the amount of such Volume Priced Components ordered pursuant to the Firm Purchase Order. In the event that QiG Group has not, in any calendar year, purchased and accepted delivery of a Volume Priced Component in such an amount that
equals or exceeds the amount of such Volume Priced Components ordered pursuant to the Firm Purchase Order for such calendar year, then QiG Group shall, within [***] days after the end of such calendar year, pay to Greatbatch an amount equal to
(i)(A) the number of such Volume Priced Components ordered pursuant to the Firm Purchase Order, minus (B) the actual number of such Volume Priced Components purchased and accepted by QiG Group during such calendar year, multiplied by
(ii) the price of such Volume Priced Component. For illustrative purposes only, if QiG Group ordered [***] IPGs pursuant to the Firm Purchase Order for 2016, but only purchased and accepted [***] IPGs in 2016, QiG Group would pay $[***] to
Greatbatch by [***] (i.e. [***] – [***] x $[***] = $[***]). 

  

	D.	In the event that QiG Group, in any calendar year, purchases and accepts delivery of a Volume Priced Component in an amount that exceeds the amount of such Volume Priced Components ordered pursuant to the Firm Purchase
Order for such calendar year, and the purchased and accepted amount would have caused a different price to be applicable if such amount would have been included in the Firm Purchase Order for such calendar year, then Greatbatch shall, within [***]
days after the end of such calendar year, issue a rebate to QiG Group in an amount equal to (i)(A) the actual number of such Volume Priced Components purchased and accepted by QiG Group during such calendar year, multiplied by (B) the price of
such Volume Priced Component as dictated by the amount set forth in the Firm Purchase Order, minus (ii)(A) the actual number of such Volume Priced Components purchased and accepted by QiG Group during such calendar year, multiplied by (B) what
the price of such Volume Priced Component would have been if the actual number of such Volume Priced Components purchased and accepted by QiG Group would have been included in the Firm Purchase Order. For illustrative purposes only, if QiG Group
ordered [***] IPGs pursuant to the Firm Purchase Order for 2016, but purchased and accepted [***] IPGs in 2016, Greatbatch would issue a rebate of $[***] to QiG Group by [***] (i.e. [[***] x $[***]] – [[***] x $[***]] = $[***]).

  

	E.	QiG Group may lock in the price for a precious metal used in a Relevant Project Component as follows: 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST.
OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 - 11 - 

	 	(i)	QiG Group will provide written notification to its Greatbatch Account Manager and customer service representative when it wants to lock in the price for a precious metal used in a Relevant Project Component. In
addition, forecast information and duration of the “price-lock” needs to be specified. 

  

	 	(ii)	Within 48 hours of receiving such notification, Greatbatch will lock in the price of the precious metal. Upon locking in the price, Greatbatch will notify QiG Group of the locked-in price. 

 

	 	(iii)	A locked-in price will become effective for the Relevant Project Component beginning the following January 1 (unless the notice provided by QiG Group under Section V.E.(ii) above is given on December 31, then
the locked-in price will not become effective until the following January 2). If QiG Group does not notify Greatbatch to lock in the price for a precious metal, the cost of the precious metal will be the market price of the precious metal
at the time of Greatbatch’s receipt of the applicable purchase order. 

  

	 	(iv)	In the event that any precious metal that is part of such “price-lock” is unused during the applicable “price-lock” period (“Unused Precious Metal”), the cost of such Unused Precious Metal
will remain the “price-lock” price until the inventory of such Unused Precious Metal is fully depleted. In the event that QiG Group elects to lock the price for a precious metal that is the same metal as the Unused Precious Metal, such
requested “price-lock” price will not be effective until the inventory of such Unused Precious Metal is fully depleted. Notwithstanding anything in this Section V.E.(iv) to the contrary, all Unused Precious Metals will be purchased by QiG
Group within ninety (90) days of the end of the applicable “price-lock” period at Greatbatch’s cost for such Unused Precious Metals. 

  

	 	(v)	In the event that Greatbatch’s inventory of any precious metal that is part of such “price-lock” is fully depleted prior to the completion of the applicable “price-lock” period, the
“price-lock” shall be terminated and the cost of the precious metal will be the market price of the precious metal at the time of Greatbatch’s next purchase of such precious metal. 

 

	F.	Greatbatch will provide Relevant Project Components to QiG Group pursuant to purchase orders to be issued by QiG Group. The general terms and conditions of 

 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 - 12 - 

	 	
sale for Relevant Project Components sold by Greatbatch to QiG Group hereunder are set forth in this Agreement. The Parties expressly agree that none of the terms and conditions of any standard
purchase preprinted forms used by either Greatbatch or the QiG Group in effectuating the purchase and sale transactions contemplated by this Agreement (including, but not limited to, purchase orders, acknowledgements and acceptance forms, invoices,
labels and shipping documents) will apply, except insofar as a purchase order or acknowledgement establishes the quantity, destination, shipping information and the desired delivery date (which must satisfy the standard lead times identified for the
applicable Relevant Project Component). 

  

	G.	QiG Group’s purchase order form shall set forth, at a minimum, the quantity of Relevant Project Components ordered, the address of the facility of QiG Group (or its affiliate) to which the Relevant Project
Components should be shipped and requested delivery dates (which shall be no less than the lead time set forth in Section VI below). 

  

	H.	Unless QiG Group gives Greatbatch written instructions as to the method of shipment and carrier, Greatbatch shall select the methods of shipment and the carrier for the respective purchase order. Greatbatch shall prepay
transportation and similar charges upon shipment. Title to all Relevant Project Components conforming to QiG Group’s purchase order shall pass, free and clear of all encumbrances, at the EXW shipping point, which shall be Greatbatch’s
facility. QiG Group assumes and agrees to bear all risk of damage or loss to the Relevant Project Components after delivery by Greatbatch to the carrier at the EXW shipping point. QiG Group hereby releases Greatbatch from any and all claims and
liability with respect to any such in-transit damages or losses to the goods. QiG Group shall be responsible for securing insurance coverage to cover shipments and deliveries hereunder. 

 

	I.	Greatbatch shall perform testing to ensure that certain Relevant Project Components delivered to QiG Group meet all applicable Specifications and such testing will be at Greatbatch’s cost, except as set forth
below. QiG Group inspection of incoming Relevant Project Components will rely upon Greatbatch testing and may consist of an examination of Greatbatch’s testing documentation as well as independent testing by QiG Group. Notwithstanding
the foregoing, QiG Group shall attempt to inspect all Relevant Project Components within thirty (30) days, but not to exceed sixty (60) days, and notify Greatbatch if any of the Relevant Project Components fail to meet the Specifications
and quality standards for such Relevant Project Components. Prior to the Effective Date, QiG Group has provided, at no cost to Greatbatch, one (1) IPG board level testing station, one 

 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 - 13 - 

	 	
(1) IPG Charging 6 Bay station, one (1) IPG Fine Tune station, one (1) IPG final functional testing station and one (1) EPG board level testing station (the “Generation 1
Stations”). On or prior to March 31, 2016, QiG Group shall provide, to Greatbatch, one (1) IPG board level testing station and one (1) IPG final functional testing station (the “Generation 1A Stations”). To the
extent that Greatbatch requests QiG Group to provide new or additional testing stations in addition to the Generation 1 or Generation 1A Stations (the “New Testing Stations”), QiG Group will use commercially reasonable efforts to develop,
design and provide such New Testing Stations on the delivery schedule requested by Greatbatch. Greatbatch will be responsible for the hardware costs of the Generation 1A Stations and New Testing Stations and such costs shall be negotiated in good
faith between the parties. Greatbatch will be responsible for its costs to validate and implement the Generation 1A Stations and New Testing Stations. 

If QiG Group provides (i) periodic revisions or improvements, both software related and mechanical/structural, to any testing stations or
(ii) new testing stations as a result of a QiG Group initiated redesign or modification, including, without limitation the Generation 2 Testing Stations expected to be delivered by QiG Group to Greatbatch in the first quarter of 2017
(collectively, the “QiG Initiated Stations”), QiG Group will be solely responsible for the cost of such revisions or improvements or such QiG Initiated Stations and QiG Group will reimburse Greatbatch for Greatbatch’s costs to
validate and implement such revisions or improvements or QiG Initiated Stations. QiG Group will be responsible for all labor costs associated with developing, designing and providing the Generation 1A Stations, New Testing Stations, and QiG
Initiated Stations. QiG Group agrees that it will provide, at no cost to Greatbatch, reasonable and necessary training, technical support and troubleshooting assistance for the Generation 1A Stations, New Testing Stations, and QiG Initiated Stations
until such time that the Generation 1A Stations, New Testing Stations or QiG Initiated Stations, as applicable, perform to a mutually agreed upon level that is to be negotiated in good faith between the Parties. Within thirty (30) days of
the expiration or termination of this Agreement, QiG Group shall purchase from Greatbatch all testing stations provided to, or purchased by, Greatbatch under this Section V.I. and the purchase price shall be the net book value of all such testing
stations at the date of expiration or termination of this Agreement. 
  

	J.	QiG Group and Greatbatch agree to use their best efforts to mutually agree on (i) a testing protocol for the Relevant Project Components and (ii) a resolution with the suppliers of the [***] to reduce the
“[***]” rate of the applicable [***], in order 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 - 14 - 

	 	
to achieve a “[***]” for the Relevant Project Components (including, all underlying [***]) of at least [***]% as soon as possible. Greatbatch and QiG Group hereby appoint Mauricio
Arellano and Norbert Kaula as their respective representatives to achieve such agreement. 

  

	K.	Commencing on [***], QiG Group shall pay to Greatbatch, in addition to the price for the IPGs and EPGs set forth in Appendix B of this Agreement, a surcharge for each IPG and EPG purchased by QiG Group during the
next [***] ([***]) months (the “[***] Surcharge”). Greatbatch and QiG Group agree to calculate the [***] Surcharge on [***] and [***] (each the “[***] Surcharge Calculation Date”), and such [***] Surcharge shall remain in effect
for [***] ([***]) months after the applicable [***] Surcharge Calculation Date. The [***] Surcharge for each IPG and EPG, as applicable, shall be calculated as follows (i)(A)(I) [***]% minus (II) the IPG or EPG [***] before final assembly, as
applicable, multiplied by (B) the cost of the IPG or EPG [***], as applicable, multiplied by (ii) [***] percent ([***]%). For purposes of calculating the [***], Greatbatch (i) will not include [***] that failed the Greatbatch incoming
inspection process, that were returned to the [***] supplier, and for which Greatbatch was issued a refund, and (ii) will include [***] that failed the [***] testing in calculating previous [***] Surcharges but that pass the [***] testing in
calculating the current [***] Surcharge and that Greatbatch will use in the production of the IPGs and EPGs, as determined in its sole reasonable discretion. For purposes of calculating the [***] Surcharge, the cost of the IPG [***] is $[***]
and the cost of the EPG [***] is $[***]. For illustrative purposes only, if an IPG has a [***] of [***]%, then QiG Group will pay a [***] Surcharge of $[***] to Greatbatch for each IPG purchased by QiG Group during the next [***] ([***]) month
period (i.e. ([[***]% – [***]%) * $[***]] * [***]% = $[***]). For illustrative purposes only, if an EPG has a [***] of [***]%, then QiG Group will pay a [***] Surcharge of $[***] to Greatbatch for each EPG purchased by QiG Group during the next
[***] ([***]) month period (i.e. ([[***]% – [***]%) * $[***]] * [***]% = $[***]). The [***] Surcharge for the IPG will be discontinued once the IPG [***] before final assembly and the IPG [***] after final assembly each achieve [***]% or [***],
whichever occurs first. The [***] Surcharge for the EPG will be discontinued once the EPG [***] before final assembly and the EPG [***] after final assembly each achieve [***]% or [***], whichever occurs first. 

 

	L.	Commencing on [***], QiG Group shall pay to Greatbatch, in addition to the price for the IPGs and EPGs set forth in Appendix B of this Agreement, a surcharge for each IPG and EPG purchased by QiG Group
during the next [***] ([***]) months (the “IPG/EPG Level Surcharge”); provided, that in the event that 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST.
OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 - 15 - 

	 	
an IPG/EPG Level Surcharge is payable with regards to the EPGs and the manufacturing of the EPGs has not yet been moved to Greatbatch’s Tijuana, Mexico facility, then the [***] Surcharge for
the EPGs shall be paid in lieu of the IPG/EPG Level Surcharge. Greatbatch and QiG Group agree to calculate the IPG/EPG Level Surcharge on [***] and every [***] ([***]) months thereafter (each calculation date, the “IPG/EPG Level Surcharge
Calculation Date”), and such IPG/EPG Level Surcharge shall remain in effect until the next IPG/EPG Level Surcharge Calculation Date. The IPG/EPG Level Surcharge for each IPG and EPG, as applicable, shall be calculated as follows (i)(A)(I)(x)
[***]% minus (y) the IPG or EPG [***] before final assembly, as applicable, multiplied by (II) the cost of the IPG or EPG [***], as applicable, multiplied by (B) [***] percent ([***]%), plus (ii)(A)(I) [***]% minus (II) the IPG or EPG
[***] after final assembly, as applicable, multiplied by (B) the price of the IPG or EPG, as applicable. For purposes of calculating the [***], Greatbatch (i) will not include [***] that failed the Greatbatch incoming inspection process,
that were returned to the [***] supplier, and for which Greatbatch was issued a refund, and (ii) will include [***] that failed the [***] testing in calculating previous [***] Surcharges or IPG/EPG Level Surcharges but that pass the [***]
testing in calculating the current IPG/EPG Level Surcharge and that Greatbatch will use in the production of the IPGs and EPGs, as determined in its sole reasonable discretion. For purposes of calculating the IPG/EPG Level Surcharge, the cost of the
IPG [***] is $[***], the cost of the EPG [***] is $[***], the price of the IPG is $[***], and the price of the EPG is $[***]. For illustrative purposes only, if an IPG has a [***] of [***]%, and a [***] of [***]%, then QiG Group will pay an IPG/EPG
Level Surcharge of $[***] to Greatbatch for each IPG purchased by QiG Group during the next [***] ([***]) month period (i.e. [([***]% – [***]%) * $[***] * [***]%] + [([***]% – [***]%) * $[***]] = $[***]). For illustrative purposes only, if
an EPG has a [***] of [***]%, and a [***] of [***]%, then QiG Group will pay an IPG/EPG Level Surcharge of $[***] to Greatbatch for each EPG purchased by QiG Group during the next [***] ([***]) month period (i.e. [([***]% – [***]%) * $[***] *
[***]%] + [([***]% – [***]%) * $[***]] = $[***]).The IPG/EPG Level Surcharge for the IPG will be discontinued once the IPG [***] before final assembly and the IPG [***] after final assembly each achieve [***]%. The IPG/EPG Level
Surcharge for the EPG will be discontinued once the EPG [***] before final assembly and the EPG [***] after final assembly each achieve [***]%. In the event that QiG Group is paying an IPG/EPG Level Surcharge on [***], QiG Group and Greatbatch agree
to use their best efforts to reduce the effects of a “[***]” for the Relevant Project Components (including, all underlying [***]) of less than [***]%. 

 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 - 16 - 

	M.	QiG Group may reject any shipments or deliveries of Relevant Project Components, which are short, nonconforming, defective or deficient and may request correction and/or replacement. Rejected shipments or deliveries of
Relevant Project Components shall at the request of Greatbatch be set aside for Greatbatch inspection, or at the request of Greatbatch shipped freight prepaid to Greatbatch. Within 48 hours of receiving returns of Relevant Project Components,
Greatbatch will host a joint call with QiG Group to discuss the return, product history and investigational plan. All Relevant Project Components returned to Greatbatch shall be accompanied by a copy of their original shipping documents and the name
and phone number of the person at QiG Group to be contacted regarding such return. Promptly upon receipt of notice of such shortage, non-conformance, defect or deficiency, Greatbatch shall immediately notify QiG Group: 

 

	 	(i)	as to how Greatbatch will replace the defective or deficient Relevant Project Components upon return to Greatbatch, ship replacement Relevant Project Components, or otherwise promptly correct such shortage,
non-conformance, or deficiency; and/or 

  

	 	(ii)	whether such shipment of Relevant Project Components shall be set aside and held by QiG Group or returned to Greatbatch and the address to which such affected Relevant Project Components should be returned, or whether
such Relevant Project Components should otherwise be disposed of. 

 If QiG Group elects to cancel or rescind such purchase,
Greatbatch shall promptly refund and reimburse QiG Group the price paid by QiG Group for such purchase, including freight and shipping costs incurred by QiG Group in connection with such purchase, prior to the return of the same to Greatbatch. If
QiG Group elects to have the Relevant Project Component replaced, Greatbatch shall bear or shall reimburse QiG Group for all costs and expenses incurred by QiG Group to repackage, ship and return affected Relevant Project Components to Greatbatch
and shall issue a credit memo for the amount of the purchase price of the returned Relevant Project Components. 
  

	N.	In the event of any act of God or any other causes beyond the control of Greatbatch, including, but not limited to, fire, explosion, strikes, war, act of any governmental agency, material or labor shortage (excluding
those related to Greatbatch’s workforce), or a delay or default caused by a common carrier (“Force Majeure”), Greatbatch shall not be liable for any delay in shipment or non-delivery of Relevant Project Components covered by
this Agreement arising from Force Majeure, and QiG Group shall be bound to accept the delayed 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST.
OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 - 17 - 

	 	
shipment or delivery made within a reasonable time. In the event of Force Majeure, QiG Group shall be excused for the failure to take and pay for Relevant Project Components ordered under this
Agreement, until such Force Majeure condition is removed. In the event such conditions cannot be corrected by the Party affected within [***] days of the date of the occurrence of a Force Majeure event, then the other Party shall have the option to
terminate this Agreement upon one (1) month prior notice. 

  

	O.	For the three year period commencing upon the Effective Date, payment terms are net [***], EXW Greatbatch’s shipping point. Commencing upon the three year anniversary of the Effective Date through the end of the
Term, payment terms will become net [***], EXW Greatbatch’s shipping point. 

  

	P.	The Parties will collaborate to identify cost reduction initiatives relating to the supply of the Relevant Project Components under this Agreement. Subject to Section IV.B. above, all savings and cost reductions (other
than those recognized in connection with any relocation of a manufacturing facility, including, without limitation, a relocation of the manufacturing facility from the Plymouth, Minnesota facility), regardless of whether identified collaboratively
or independently by either party, will be shared by the parties as set forth below and each party will disclose to the other any such savings that it acquires or generates. Subject to Section IV.B. above, in the event that Greatbatch and QiG Group
are willing to share the expenses associated with the implementation of any such cost proposal (other than any relocation of a manufacturing facility, including, without limitation, a relocation of the manufacturing facility from the Plymouth,
Minnesota facility), cost savings shall be split [***] percent ([***]%) to Greatbatch and [***] percent ([***]%) to QiG Group; provided, that any such cost savings shall not be split until each Party has fully recovered its expenses associated with
any such cost proposal. The Parties will recover their expenses [***] (e.g. if Greatbatch invests $[***] and QiG Group invests $[***] in the cost proposal, Greatbatch will receive $[***] for every $[***] recovered by QiG Group prior to the split of
the cost savings). Greatbatch shall give QiG Group notice of the implementation of cost reductions as soon as practicable, but in any event within thirty (30) days of the accomplished reduction. Thereafter, all invoices shall reflect the
applicable reduced pricing and the Parties shall work to update Appendix B accordingly. 

  

	VI.	LEAD TIME: 

 Standard lead time for the manufacturing of the Relevant
Project Components is twelve (12) weeks unless the Parties otherwise agree in writing. Greatbatch will use 
  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST.
OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 - 18 - 

 
commercially reasonable efforts to deliver the Relevant Project Components in accordance with the foregoing lead time. 
  

	VII.	FORECAST PLANNING: 

 On a monthly basis, QiG Group will provide [***]
([***]) months firm orders and an additional [***] ([***]) months forecasts stating its anticipated needs for Relevant Project Components. This will provide Greatbatch with a total of [***] months projected requirements for planning purposes at all
times. A new firm order requirement and the next month forecasted quantity will be provided each succeeding month. Forecasts covering QiG Group’s [***]-month anticipated needs are non-binding and are for planning purposes only. 

Greatbatch will hold at least [***] ([***]) weeks of supply of the Relevant Project Components, [***] ([***]) of which will be in the form of
finished goods and [***] ([***]) of which will be in the form of WIP (collectively, the “Safety Stock”). This [***] ([***]) week amount will be determined based on the rolling [***] ([***]) month forecast described in the preceding
paragraph. The Safety Stock will satisfy any purchase order according to FIFO (First In First Out) unless otherwise agreed to by the Parties in writing. QiG Group will be responsible for purchasing any Relevant Project Component that remains in
Safety Stock for at least [***] ([***]) months. 
  

	VIII.	CONSIGNMENT 

  

	 	A.	Simultaneous with the execution of the Agreement, and on a monthly basis thereafter, QiG Group will provide Greatbatch with a [***] ([***]) month rolling forecast of QiG Group’s reasonably expected monthly order
volume for the Relevant Project Components to be consigned at QiG Group’s Blaine, Minnesota location (the “Consigned Products”) for the forthcoming [***] ([***]) month period. QiG Group will update the forecast monthly. QiG
Group shall order Consignment Product by issuance of a purchase and/or blanket order (each, a “Consignment Order”) to Greatbatch. Consignment Orders which conform to the terms of this Agreement shall be deemed to be accepted by
Greatbatch and Greatbatch will acknowledge receipt of such Consignment Order by written notice to QiG Group, (“Acknowledged Order”). Greatbatch will use commercially reasonable efforts to accept any orders or blanket orders that do
not conform to the terms of this Agreement. Greatbatch shall deliver such Consignment Products in accordance with the delivery schedule specified by QiG Group in the Consignment Order. 

 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 - 19 - 

	B.	Upon receipt of a Consigned Product, QiG Group shall track the Consignment Products received (“Consignment Inventory”) and copies of the tracking reports shall be furnished to Greatbatch upon request.
Consignment Inventory shall be identified as the property of Greatbatch. The Consignment Products shall be segregated from other goods either of the same or different character belonging either to QiG Group or to any third party and shall be stored
in an area in QiG Group’s (or its designee’s) facility separate from and not mingled with other goods of QiG Group or of any third party. Upon reasonable advance written notice and no more than once in any calendar quarter, Greatbatch
shall have reasonable access to the Consignment Products at QiG Group’s facility for the purposes of verifying tracking reports or inspecting the condition of the Consignment Products. In the event of a threatened or actual breach of the
Agreement by QiG Group, Greatbatch shall have immediate access to the Consignment Products for the purposes of verifying tracking reports or inspecting the condition of the Consignment Products. The Parties agree that the volume of Consignment
Inventory will be taken into account when calculating the amount of Greatbatch’s Safety Stock. Notwithstanding anything in this Agreement to the contrary, in no event will the Consignment Inventory exceed [***] ([***]) weeks of supply of the
Relevant Project Components and Greatbatch shall have no obligation to deliver any Relevant Project Components to QiG Group for so long as the Consignment Inventory equals or exceeds [***] ([***]) weeks of supply of the Relevant Project Components.
This [***] ([***]) week amount will be determined based on the rolling [***] ([***]) month forecast described in Section VIII.A. above. 

  

	C.	If QiG Group receives any Consignment Products which do not meet the applicable Specifications, QiG Group shall notify Greatbatch within two weeks of discovery or determination that the Consignment Products do not meet
Specifications, and Greatbatch shall retrieve such Consignment Products from QiG Group at Greatbatch’s sole expense, and QiG Group shall not be required to pay for any such Consignment Products. Notwithstanding the immediately preceding
sentence, QiG Group may not return, and QiG Group will be responsible for paying the applicable price for, any Consignment Product if any repair, alteration, modification or work has been performed on such Consignment Product, or if the alleged
defect is the result of abuse, misuse, improper maintenance or storage, accident, action or inaction on the part of any QiG Group, its agents or representatives or any third party after delivery of the Consignment Products to QiG Group or its
designee. 

  

	D.	Upon QiG Group transferring any Consignment Product out of Consignment Inventory and (i) into QiG Group’s or its designee’s manufacturing area or (ii) out 

 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 - 20 - 

	 	
of QiG Group’s Blaine, Minnesota facility (“Transfer Date”) such Consignment Product shall become the property of QiG Group and title to such Consignment Product shall pass
to QiG Group. QiG Group shall notify Greatbatch every Monday (or the next business day, if Monday is not a business day) of the quantity of components and part numbers of Consignment Products transferred the prior week via a consignment
reconciliation document, and Greatbatch shall send QiG Group an invoice for the transferred Consignment Products. QiG Group shall pay such invoice within [***] days for invoices issued during the three year period commencing upon the Effective Date
and within [***] days for invoices issued during the period commencing upon the three year anniversary of the Effective Date through the end of the Term. All reconciliations and payments will be in US dollars. 

 

	E.	All Consignment Products stored on QiG Group’s or its designee’s premises shall be Greatbatch’s property until the Transfer Date, and QiG Group may return Consignment Product to Greatbatch at any time
prior to such Transfer Date. QiG Group shall withdraw the Consignment Products on a FIFO (First In First Out)basis for each type of Consignment Product. QiG Group will be responsible for purchasing any Consignment Product that remains in Consignment
Inventory for at least six (6) months. QiG Group shall be responsible for, and shall indemnify and hold harmless Greatbatch against, any loss, damage, shrinkage or spoilage, to the Consignment Products while at QiG Group’s or its
designee’s facility. QiG Group shall maintain insurance, which may include a program of self insurance, covering such losses. 

  

	F.	QiG Group will not sell, transfer, assign, pledge, grant a security interest in or otherwise encumber or allow any third party to obtain an interest in any Consignment Products in Consignment Inventory. QiG Group shall
comply with all Legal Requirement which might in any way affect Greatbatch’s ownership of the Consignment Products and shall defend, indemnify and hold harmless Greatbatch from and against all losses, damages and expenses arising out of any
levy, attachment, lien or process involving the Consignment Products to the extent caused by QiG Group, its agents or representatives. 

  

	G.	If the quantity of any Consignment Product ordered by QiG Group for any month is collectively less than [***] percent ([***]%) of the quantity ordered for the preceding month, the Parties shall participate in a
telephone conference to discuss the reason for QiG Group’s decrease in consumption of such Consignment Product. If in the month immediately following such decrease in consumption of such Consignment Product, the quantity ordered is collectively
less than or equal 

  
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION. 

  
 - 21 - 

	 	
to the quantity ordered for the preceding month, Greatbatch and QiG Group may agree on a new level of Consignment Inventory for such Consignment Product. 

 

	H.	Subject to the first sentence of Section VIII.C, all charges and expenses for shipping, receiving, handling and storing the Consignment Products shall be paid by QiG Group. All public charges, whether in the nature of
sales, occupational or other taxes (excluding taxes levied on the income of Greatbatch) or assessment or license fees, which shall be levied or assessed against the Consignment Products at QiG Group’s or its designee’s facility, or against
QiG Group or Greatbatch by reason hereof, by any federal, state or municipal authority, shall be paid by QiG Group. 

  

	I.	QiG Group shall provide Greatbatch with at least [***] ([***]) days’ written notice if any Consignment Product shall be discontinued or replaced. The Parties shall discuss in good faith any needed adjustment in the
rolling forecast and in any Consignment Order for such Product or Products as a result of such planned discontinuance or replacement. 

  

	IX.	CANCELLATION CHARGES: 

 In the event that QiG Group cancels a purchase order inside the
agreed upon lead time, QiG Group will be responsible for all finished Relevant Project Components, WIP and raw materials and components. In the event that QiG Group cancels a purchase order outside of agreed upon lead time, QiG Group and Greatbatch
will negotiate resulting costs. 
  

	X.	WARRANTY, INDEMNITY AND LIABILITY LIMITATION: 

  

	 	A.	Limited Warranty: 

  

	 	(i)	Greatbatch warrants that all of the Relevant Project Components sold to QiG Group under this Agreement shall be in conformance with the Specifications and the Quality Agreement applicable to such Relevant Project
Components and shall be free from defects in material and workmanship for a period of eighteen (18) months from the date of delivery (the “Warranty Period”). Subject to the limitations set forth in the following sentence, if
any Relevant Project Components do not meet the applicable Specifications and QiG Group shall have timely notified Greatbatch, Greatbatch will replace such Relevant Project Components free of charge and will reimburse QiG Group for reasonable out-of-pocket expenses (including freight and customs clearance, if any) incurred by QiG Group in connection with (a) shipment of replacement Relevant 

 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 - 22 - 

	 	
Project Components to the same location and (b) shipment of the nonconforming Relevant Project Components back to Greatbatch (if so requested by Greatbatch). 

The warranty provided in this Section X.A. shall not apply to any Relevant Project Component failure occurring as a result of any of the
following: (x) any abuse, misuse, neglect or attempted disassembly of a Relevant Project Component, or any alteration or modification of a Relevant Project Component without the express written consent of Greatbatch; (y) any improper
operation, improper installation, or any other use inconsistent with any applicable law, rule, regulation or governmental directive; or (z) any use inconsistent with the then current specifications of Greatbatch for the Relevant Project
Components or with any warning or recommended operating practice specific to the Relevant Project Components that may be provided to QiG Group from time to time by Greatbatch in writing. 

 

	 	(ii)	THE WARRANTY PROVIDED IN SECTION X.A(i) ABOVE IS THE SOLE AND EXCLUSIVE WARRANTY GIVEN BY GREATBATCH WITH RESPECT TO THE RELEVANT PROJECT COMPONENTS. GREATBATCH MAKES NO OTHER WARRANTY AND HEREBY EXPRESSLY DISCLAIMS ALL
OTHER REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, AND NO IMPLIED WARRANTY SHALL ARISE BY USAGE OF TRADE, COURSE OF DEALING
OR COURSE OF PERFORMANCE. NO REPRESENTATIVE OF GREATBATCH IS AUTHORIZED TO GIVE OR MAKE ANY OTHER REPRESENTATION OR WARRANTY OR TO MODIFY THE FOREGOING WARRANTY IN ANY WAY. 

 

	 	B.	LIMITATION OF LIABILITY. NOTWITHSTANDING ANYTHING IN THIS AGREEMENT TO THE CONTRARY, IN NO EVENT SHALL GREATBATCH BE LIABLE TO QIG GROUP (X) FOR BREACH OF WARRANTY OR BASED UPON ANY OTHER THEORY UNDER
THIS AGREEMENT FOR AN AMOUNT IN EXCESS OF THE TOTAL AMOUNT THAT QIG GROUP HAS PAID OR THAT IS PAYABLE TO GREATBATCH UNDER THIS AGREEMENT FOR THE IMMEDIATELY PRECEDING 12 MONTH PERIOD, BUT IN NO EVENT MORE THAN $10 MILLION, BUT SUCH LIMITATION WILL
NOT APPLY TO GREATBATCH’S INDEMNIFICATION 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 - 23 - 

	 	
OBLIGATIONS UNDER SECTION X.D OR (Y) FOR ANY LOST PROFITS OR ANY CONSEQUENTIAL, INDIRECT, INCIDENTAL, EXEMPLARY OR SPECIAL DAMAGES OF ANY KIND. 

 

	 	C.	QiG Group hereby agrees to indemnify and hold harmless Greatbatch and any officer, director, employee, or stockholder of Greatbatch (the “Greatbatch Indemnitees”) from and against any and all losses,
damages, liabilities, expenses, costs or damages arising out of or related to any claim or lawsuit against any Greatbatch Indemnitees: 

  

	 	(i)	on account of personal injury or death to any person, resulting from the use of any Product of QiG Group in which any Relevant Project Components are used, unless both of the following facts are
present: (a) one of the Relevant Project Components was not manufactured by Greatbatch within the Specifications for such Relevant Project Components provided for in this Agreement, and (b) such Relevant Project Components was the
sole and direct cause in the failure of any Product that gives rise to any such personal injury or death; 

  

	 	(ii)	for infringement of any patent or intellectual property rights of any third party as a result of Greatbatch’s use of a QiG Group design for the Relevant Project Component or Product; 

 

	 	(iii)	for any violation of law by QiG Group; and 

  

	 	(iv)	for the gross negligence or willful misconduct of QiG Group. 

 QiG Group will defend, manage
and assume all costs of any lawsuit or claim related to the indemnification provided for in this Section X.C. Greatbatch will notify QiG Group promptly after Greatbatch becomes aware of any claim by any third party with respect to which
Greatbatch would be entitled to indemnification hereunder. Greatbatch will not settle or offer to settle any such claim or lawsuit without QiG Group’s prior written approval. 

 

	 	D.	Greatbatch hereby agrees to indemnify and hold harmless QiG Group from and against any and all losses, damages, liabilities, expenses, costs or damages arising out of or related to any claim or lawsuit against QiG Group
or any officer, director, employee, stockholder or agent of QiG Group (the “QiG Group Indemnitees”): 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST.
OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 - 24 - 

	 	(i)	on account of personal injury or death to any person, resulting from the use of any Relevant Project Components in any Product of QiG Group, unless either of the following facts are present: (a) the Relevant
Project Component(s) were manufactured by Greatbatch within the Specifications for such Relevant Project Components provided by QiG Group, and (b) the Relevant Project Component(s) was not the sole and direct cause in the failure of the Product
that gives rise to any such personal injury or death; 

  

	 	(ii)	for infringement of any patent or intellectual property rights of any third party as a result of QiG Group’s use of a Greatbatch design for a Relevant Project Component; 

 

	 	(iii)	for any violation of law by Greatbatch; and 

  

	 	(iv)	for the gross negligence or willful misconduct of Greatbatch. 

 Greatbatch will defend, manage
and assume all costs of any lawsuit or claim related to the indemnification provided for in this Section X.D. QiG Group will notify Greatbatch promptly after QiG Group becomes aware of any claim by any third party with respect to which QiG Group
would be entitled to indemnification hereunder. QiG Group will not settle or offer to settle any such claim or lawsuit without Greatbatch’s prior written approval. 
  

	 	E.	Insurance. 

  

	 	(i)	Each Party shall procure and maintain products liability and completed products insurance and cause each of its insurers to issue an endorsement to the following insurance policies adding the other Party as an
additional insured. The insurance required under this Section X.E. must include the following coverage limits: 

  

	 	(a)	Bodily Injury: 

  

	 	    	$[***] Each Occurrence 

	 	    	$[***] General Aggregate 

  

	 	(b)	Property Damage: 

  

	 	    	$[***] Each Occurrence 

	 	    	$[***] General Aggregate. 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST.
OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 - 25 - 

	 	(ii)	The insurance must be maintained at all times during this Agreement and for a minimum period of two years after this Agreement is terminated, and each Party must continue to provide evidence of such coverage to the
other Party on an annual basis during that period. In addition: 

  

	 	(a)	The coverage afforded under any insurance policy a Party obtains must be primary to any valid and collectible insurance that the other Party may carry; any insurance policies issued to the other Party shall only apply,
if at all, as excess insurance.

  

	 	(b)	Any insurance policy a Party obtains must provide that at least 30 days prior written notice shall be given to the other Party in the event of any material change, cancellation or expiration of the coverage under the
policy. 

  

	 	(c)	A Party must deliver to the other Party, within 10 days after the date the Party executes this Agreement, copies of all insurance policies required to be procured by the Party under this Agreement. If any insurance
required under this Agreement expires or is replaced, the Party must supply the other Party with declarations pages, mandatory riders and endorsements listing the other Party as an additional insured and evidencing the continuation of all required
coverages. The other Party’s failure to receive copies of the insurance policies required under Section X.E(ii) above, or to demand such copies before the other Party begins work, shall not be construed as the other Party’s waiver of
the first Party’s obligations to obtain the required insurance. 

  

	 	(d)	If a Party or its insurer(s) make(s) any payment toward any loss covered under any policy of insurance that the other Party is required to procure under this Agreement, the Party’s insurer(s) shall be subrogated to
all of the other Party’s rights of recovery against any person or organization including, but not limited to, the other Party’s insurer(s), and the other Party must execute and deliver all papers and anything else that is necessary to
secure those rights. 

  

	 	F.	The Parties will cooperate fully with each other with respect to any mandatory safety related formal recall of any Product ordered by, or in consultation with, any regulatory authority. In the event of any such recall,
replacement or field corrective action resulting from a product defect in any Related Project 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST.
OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 - 26 - 

	 	
Component, Greatbatch will repair or replace such defective Related Project Component at its own cost and expense. 

 

	XI.	CONFIDENTIALITY 

  

	 	A.	Identification of Confidential Information. Confidential Information provided by one Party (as applicable, the “disclosing party”) to any other Party (as applicable, the “receiving
party”) and entitled to protection under this Agreement shall be identified as such by appropriate markings on any documents exchanged. If the disclosing party provides information other than in written form, such information shall be
considered Confidential Information only if (i) the information by its nature would reasonably be considered of a confidential nature or if the receiving party, due to the context in which the information was disclosed, should have reasonably
known it to be confidential, and (ii) either the disclosing party gives written notice within thirty (30) days of disclosure that such information is to remain confidential or the disclosing party had previously confirmed in writing that
such information was confidential. 

  

	 	B.	Protection of Confidential Information. Each Party acknowledges that the other Party claims its Trade Secrets and other Confidential Information as special, valuable and unique assets. During the Restricted
Period (as defined below) for itself and on behalf of its officers, directors, agents, and employees, each Party agrees to the following: 

  

	 	(i)	The receiving party will not disclose any Confidential Information to any third party or disclose to an employee unless such third party or employee has a need to know such Confidential Information in order to enable
the disclosing party to exercise its rights or perform its obligations under this Agreement and such third party or employee is subject in writing to substantially the same confidentiality obligations as the Parties. The receiving party will use the
Confidential Information only for the purposes of exercising its rights or fulfilling its obligations under this Agreement and will not otherwise use it for its own benefit. In no event shall the receiving party use less than the same degree of care
to protect the Confidential Information as it would employ with respect to its own information of like importance which it does not desire to have published or disseminated. 

 

	 	(ii)	If the receiving party faces legal action or is subject to legal proceedings requiring disclosure of Confidential Information, then, prior to disclosing any such Confidential Information, the receiving party shall
promptly 

  
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF
THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 - 27 - 

	 	
notify the disclosing party and, upon the disclosing party’s request, shall cooperate with the disclosing party in contesting such request or in obtaining a protective order or other similar
injunctive relief. 

  

	 	(iii)	The Parties acknowledge that monetary damages may not be sufficient remedy for a breach of obligation of confidentiality in this Agreement and agree that each Party shall be entitled to seek appropriate equitable
remedies, including injunctive relief, to prevent the unauthorized use or disclosure of any Confidential Information. 

  

	 	(iv)	For purposes hereof, the term “Restricted Period” means (a) in the case of the Trade Secrets of a disclosing party, in perpetuity; and (b) in the case of other Confidential Information of a
disclosing party, during the term of this Agreement and for five years thereafter. 

  

	 	C.	Return of Confidential Information. All information furnished under this Agreement shall remain the property of the disclosing party and shall be returned to it or destroyed or purged promptly as its request upon
termination of this Agreement; provided, however, that (i) QiG Group may retain Confidential Information of Greatbatch as reasonably necessary for QiG Group to be able to complete the use of Relevant Project Components on order or in inventory
at the time of termination and to support Relevant Project Components already used by QiG Group in the Products, and (ii) Greatbatch may retain Confidential Information of QiG Group as reasonably necessary to fulfill its obligations under this
Agreement. All documents, memoranda, notes and other tangible embodiments whatsoever prepared by the receiving party based on or which includes Confidential Information shall be destroyed to the extent necessary to remove all such Confidential
Information upon the disclosing party’s request. An authorized officer of the receiving party shall, upon written request of the disclosing party, certify all destruction under this Section XI.C in writing to the disclosing party.

  

	 	D.	Limitations. The confidentiality obligations in this Article XI shall not apply to disclosed information which the receiving party can prove: (a) was already part of the public domain at the time of the
disclosure by the disclosing party; (b) becomes part of the public domain through no fault of the receiving party (but only after and only to the extent that it is published or otherwise becomes part of the public domain); (c) was in the
receiving party’s possession prior to the disclosure by the disclosing party and was not acquired, directly, or indirectly, from the disclosing party or from a third party who was under a continuing obligation of confidence to the disclosing
party; (d) is received (after the 

  
 CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION. 

  
 - 28 - 

	 	
disclosure by the disclosing party) by the receiving party from a third party who did not require the receiving party to hold it in confidence and did not acquire it directly or indirectly, from
the disclosing party under a continuing obligation of confidence; or (e) is disclosed by the receiving party pursuant to judicial compulsion, provided that the receiving party uses reasonable effort to notify the disclosing party at the time
such judicial action is initiated. 

  

	 	E.	Public Announcements. Notwithstanding anything to the contrary contained in this Agreement, neither Party may initiate or make any public announcement or other disclosure concerning the terms and conditions or
the subject matter of this Agreement to any third party without the prior written approval of the other Party except as may be required by law. In those circumstances where either Party believes that any such disclosure is required by law, it shall
(i) notify the other Party on a timely basis in advance, and (ii) use its best efforts to seek confidential treatment of the material provisions of this Agreement to the greatest extent permitted by law. 

 

	XII.	INTELLECTUAL PROPERTY 

  

	 	A.	Background Intellectual Property. All Intellectual Property of QiG Group first conceived and reduced to practice either prior to the Effective Date or independent of performance of this Agreement will remain the
exclusive property of QiG Group. All Intellectual Property of Greatbatch first conceived and reduced to practice either prior to the Effective Date or independent of performance of this Agreement will remain the exclusive property of Greatbatch.

  

	 	B.	Ownership of Newly Created Intellectual Property. 

  

	 	(i)	All Intellectual Property developed solely by a Party or acquired from a third party by a Party during the Term, whether in connection with this Agreement or otherwise, (“Improvements”) will be owned
solely by such Party. 

  

	 	(ii)	The Parties agree that: 

  

	 	(a)	Any Intellectual Property resulting from the joint contributions of Greatbatch and QiG Group personnel or contractors during the Term will be “Joint IP”. For purposes hereof, the sole standard for
establishing whether or not any Intellectual Property is Joint IP will be that if the Intellectual Property in question were going to be patented under the laws of the United States (whether patentable or 

 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 - 29 - 

	 	
not), an employee of each Party would be required to be named as an inventor in order for the patent to be legally valid and enforceable. All Joint IP will be owned jointly by the Parties. Joint
IP will be subject to all of the terms and conditions of this Agreement. There will be no duty to account to the other Party for any use, sale or license of any Joint IP owned jointly by the Parties. Each Party will execute, and will cause its
employees and contractors and its Affiliates’ employees and contractors to execute, such assignments as may be necessary or advisable under law to effectuate the intent of this Section XII.B.(ii). 

 

	 	(b)	To the extent that any right, title or interest in or to any Intellectual Property vests in a Party, by operation of Legal Requirement or otherwise, in a manner contrary to the agreed upon ownership as set forth in this
Agreement, such Party shall, and hereby does, irrevocably assign to the other Party any and all such right, title and interest in and to such Intellectual Property to the other Party, in a manner consistent with this Agreement without the need for
any further action by any Party. 

  

	 	(c)	Each Party will be solely responsible for determining whether to file and prosecute any patent application for any of its exclusively owned Intellectual Property, including, but not limited to, existing Intellectual
Property, in any jurisdiction, paying all legal expenses, filing fees and maintenance fees relating thereto, and for determining whether and when to enforce its rights in any such Intellectual Property. 

 

	 	(d)	The Parties shall jointly determine whether or not to file and prosecute a patent application for any Resultant Patents covering Joint IP, and, if so, in which jurisdictions and for how long. Greatbatch shall be
entitled to propose patent counsel for any such application and patent prosecution, subject to QiG Group’s approval which shall not be unreasonably withheld. All legal expenses, filing fees and maintenance fees for all Resultant Patents shall
be shared equally both during the Term and after the termination of this Agreement for Joint IP. After termination of this Agreement, if a Party no longer desires to contribute to the fees or expenses for any Resultant Patent that is jointly owned,
it shall notify the other Party on a timely basis, who shall have the option to elect to maintain such patent. In such event, the Party 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST.
OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 - 30 - 

	 	
desiring not to pay fees or expenses shall assign such patent to the other Party and have no right to make, use or sell a product covered by a Resultant Patent. 

 

	 	(e)	Each Party shall promptly notify the other Party of any infringement or threatened infringement of any Joint IP, including, but not limited to, a Resultant Patent. During the Term, the Parties shall determine what
enforcement actions are appropriate with respect to jointly owned, Joint IP and shall cooperate with respect thereto. After the termination of this Agreement, each Party may enforce its rights to any jointly owned, Joint IP, and agrees and consents
to be named by the other Party as a nominal party plaintiff in connection therewith. 

  

	 	(f)	The provisions governing Joint IP set forth in this Article XII shall survive the expiration or termination of this Agreement. 

  

	XIII.	MISCELLANEOUS: 

  

	 	A.	No Waiver. The failure of any Party to enforce at any time or for any period any of the provisions of this Agreement shall not be construed to be waiver of those provisions or of the right of that Party
thereafter to enforce each and every provision hereof. 

  

	 	B.	Assignment. This Agreement shall be binding upon, and shall inure to the benefit of, the Parties’ respective successors and permitted assigns. This Agreement shall not be assignable by any Party without the
prior written consent of the other Party; provided, however, that, upon thirty (30) days’ prior written notice to the other Party but without the other Party’s prior consent, a Party (i) may assign this Agreement,
in whole or in part, to any of its Affiliates provided that the assigning Party shall remain primarily liable under this Agreement and/or (ii) shall assign this Agreement to the successor to such Party in connection with a Change of Control of
such Party provided that such successor, in the reasonable judgment of the other Party, is able to perform the assigning Party’s obligations under this Agreement. 

 

	 	C.	Notices. Unless otherwise provided in this Agreement, any notice to be given hereunder shall be in writing and (a) delivered personally (to be effective when so delivered), (b) mailed by registered or
certified mail, return receipt requested (to be effective four days after the date it is mailed) or (c) sent by Federal Express or other overnight courier service (to be effective when received by the addressee), 

 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 - 31 - 

	 	
to the following addresses (or to such other addresses which any Party shall designate in writing to the other Party): 

If to Greatbatch: 

Greatbatch Ltd. 

10000 Wehrle Drive 

Clarence, NY 14031 

Attention: General Counsel 

If to QiG Group: 

QiG Group LLC 

5830 Granite Parkway, Suite 1100 

Plano, Texas, 75024 

Attention: Chief Executive Officer 
  

	 	D.	Routine Communication. Notwithstanding the provisions of Section XIII.C, routine communications may be sent by first-class mail, postage prepaid. 

 

	 	E.	Successors and Assigns. This Agreement is binding on and inures to the benefit of the Parties and their respective permitted successors and permitted assigns. 

 

	 	F.	Injunctive Relief. The Parties hereto agree that irreparable harm would occur in the event that any of the agreements or provisions of this Agreement were not performed fully by the Parties hereto in accordance
with their specific terms or conditions or were otherwise breached, and that money damages are an inadequate remedy for breach of the Agreement because of the difficulty of ascertaining and quantifying the amount of damage that will be suffered by
the Parties hereto in the event that this Agreement is not performed in accordance with its terms or conditions or is otherwise breached. It is accordingly hereby agreed that the Parties hereto shall be entitled to seek an injunction or injunctions,
without the necessity of proving actual damages, to restrain, enjoin and prevent breaches of this Agreement by the other Parties and to enforce specifically the terms and provisions of this Agreement in any court of the United States or any
state having jurisdiction, such remedy being in addition to, and not in lieu of, any other rights and remedies to which the other Parties are entitled to at law or in equity. 

 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 - 32 - 

	 	G.	Governing Law. This Agreement shall be construed in accordance with and governed by the laws of the State of New York, without giving effect to the provisions, policies or principles thereof relating to
choice or conflict of laws. 

  

	 	H.	Waiver of Jury Trial. Each Party acknowledges and agrees that any controversy that may arise under this Agreement, including any appendices attached to this Agreement, is likely to involve complicated and
difficult issues and, therefore, each such Party irrevocably and unconditionally waives any right it may have to a trial by jury in respect of any legal action arising out of or relating to this Agreement, including any appendices attached to this
Agreement, or the transactions contemplated hereby. 

  

	 	I.	No Third-Party Beneficiaries. This Agreement benefits solely the Parties to this Agreement and their respective permitted successors and permitted assigns and nothing in this Agreement, express or implied,
confers on any other Person any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Agreement. 

  

	 	J.	Titles of Sections. The section and other headings contained in this Agreement are for reference purposes only and shall not affect the meaning or interpretation of this Agreement. 

 

	 	K.	Entire Agreement. This Agreement constitutes the entire agreement among the Parties hereto with respect to the subject matter hereof, and supersedes any prior agreement or understanding among the Parties hereto
with respect to the subject matter hereof. Except as provided otherwise herein, this Agreement may not be amended nor may any rights hereunder be waived except by an instrument in writing signed by the Party sought to be charged with such amendment
or waiver. The recitals hereto are true and correct, and are part of this Agreement. 

  

	 	L.	Counterparts. This Agreement may be executed either directly or by an attorney-in-fact, in any number of counterparts of the signature pages, each of which shall be considered an original. Facsimile or pdf
transmission of an executed counterpart of this Agreement shall be deemed to constitute due and sufficient delivery of such counterpart, and such facsimile or pdf signatures shall be deemed original signatures for purposes of enforcement and
construction of this Agreement. 

  

	 	M.	Separability. Any provision of this Agreement which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without
invalidating the 

  
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION. 

  
 - 33 - 

	 	
remaining portions hereof or affecting the validity or enforceability of such provision in any other jurisdiction. 

 

	 	N.	Purchases Prior to Effective Date. While this Agreement is being executed as of the Effective Date, the Parties agree that the terms of this Agreement, including, without limitation, Article X hereof, shall apply
to all Relevant Project Components sold by Greatbatch to QiG Group prior to the Effective Date. 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST.
OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 - 34 - 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed by their authorized
representatives. 
  

									
	QiG Group, LLC	  		  	Greatbatch Ltd.
					
	By:	  	 	  		  	By:	  	 
	Title:	  	 	  		  	Title:	  	 

  
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS
OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 LIST OF APPENDICES 

Appendix A - Description of Relevant Project Components and Specifications 

Appendix B - Prices 
  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST.
OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 APPENDIX A 

TO SUPPLY AGREEMENT 

Description of Relevant Project Components and Specifications 

Implantables 
  

															
	 Greatbatch
US Number
	  	 Greatbatch OUS
Number
	  	 QiG Model
Number
	  	 QiG Catalogue
Number
	  	 Specification
	  	 Specification
Revision
	  	 Device
Description
	  	 Geography

	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST.
OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

															
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST.
OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  

															
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS
OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 Accessories 

 

															
	 Greatbatch
US Number
	  	 Greatbatch OUS
Number
	  	 QiG Model
Number
	  	 QiG Catalogue
Number
	  	 Specification
	  	 Specification
Revision
	  	 Device
Description
	  	 Geography

	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST.
OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

															
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  

	*	Models 5600, 5410, 5301, 5311, 5401, 5420, 5530, 5501, 5511, 5520-45, 5520-60, 5520-75, 5520-90, 5526-45, and 5526-60 have not transferred from Development (QiG) to Production (PLY) 

 

	**	Catalogue rev 1.9 indicates models 5410 and 5500 are Obsolete, but items have forecasted volumes in forecast dated 11NOV2015 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST.
OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 External Devices*** 

 

															
	 Greatbatch US
Number
	  	 Greatbatch OUS
Number
	  	 QiG Model
Number
	  	 QiG Catalogue
Number
	  	 Specification
	  	 Specification
Revision
	  	 Device
Description
	  	 Geography

	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  

	***External	Devices are currently manufactured by Minnetronix 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST.
OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  

 APPENDIX B 

TO SUPPLY AGREEMENT 

Prices 
 IPG Pricing

  

											
	 Annual Volume
	  	2016	 	2017	 	2018	 	2019	 	2020
	[***]	  	$[***]	 	$[***]	 	$[***]	 	$[***]	 	$[***]
	[***]	  	$[***]	 	$[***]	 	$[***]	 	$[***]	 	$[***]
	[***]	  	$[***]	 	$[***]	 	$[***]	 	$[***]	 	$[***]
	[***]	  	$[***]	 	$[***]	 	$[***]	 	$[***]	 	$[***]
	[***]	  	$[***]	 	$[***]	 	$[***]	 	$[***]	 	$[***]
	[***]	  	$[***]	 	$[***]	 	$[***]	 	$[***]	 	$[***]
	[***]	  	$[***]	 	$[***]	 	$[***]	 	$[***]	 	$[***]
	[***]+	  	$[***]	 	$[***]	 	$[***]	 	$[***]	 	$[***]

 The parties hereby acknowledge and agree that they will be negotiating in good faith an amendment to this Agreement to add the
Pelvistim product line to this Agreement (the “Pelvistim Amendment”). The parties hereby agree that so long as the specifications of the Pelvistim IPG are materially and substantially similar to the Specifications of the Algovita IPG (with
the exception of the firmware), the price for the Pelvistim IPG will be [***] as the Algovita IPG pricing set forth above; provided, that in the event that the specifications of the Pelvistim IPG are not materially and substantially similar to the
Specifications of the Algovita IPG (with the exception of the firmware), the parties will negotiate in good faith an adjustment to the price of the Pelvistim IPG. For purposes of calculating the annual volumes above, the total quantities of the
Algovita IPGs and the Pelvistim IPGs purchased and delivered in the relevant calendar year shall be combined. 
  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST.
OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 Leads/Extensions Pricing 

 

											
	 Annual Volume
	  	2016	 	2017	 	2018	 	2019	 	2020
	[***]	  	$[***]	 	$[***]	 	$[***]	 	$[***]	 	$[***]
	[***]	  	$[***]	 	$[***]	 	$[***]	 	$[***]	 	$[***]
	[***]	  	$[***]	 	$[***]	 	$[***]	 	$[***]	 	$[***]
	[***]	  	$[***]	 	$[***]	 	$[***]	 	$[***]	 	$[***]
	[***]	  	$[***]	 	$[***]	 	$[***]	 	$[***]	 	$[***]
	[***]	  	$[***]	 	$[***]	 	$[***]	 	$[***]	 	$[***]
	[***]	  	$[***]	 	$[***]	 	$[***]	 	$[***]	 	$[***]
	[***]	  	$[***]	 	$[***]	 	$[***]	 	$[***]	 	$[***]
	[***]	  	$[***]	 	$[***]	 	$[***]	 	$[***]	 	$[***]
	[***]	  	$[***]	 	$[***]	 	$[***]	 	$[***]	 	$[***]
	[***]	  	$[***]	 	$[***]	 	$[***]	 	$[***]	 	$[***]
	[***]+	  	$[***]	 	$[***]	 	$[***]	 	$[***]	 	$[***]

 The parties hereby agree that the price for the Pelvistim Leads/Extensions with the specifications set forth in that certain
[***] (the “Pelvistim Lead/Extension Specifications”) will [***] the Algovita Leads/Extensions pricing set forth above; provided, that in the event that the Pelvistim Lead/Extension Specifications materially change prior to the execution
of the Pelvistim Amendment, the parties will negotiate in good faith an adjustment to the price of the Pelvistim Leads/Extensions. For purposes of calculating the annual volumes above, the total quantities of the Algovita Leads/Extensions and the
Pelvistim Leads/Extensions purchased and delivered in the relevant calendar year shall be combined. 
  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST.
OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 Minnetronix Externals Pricing 

 

			
	 ALL VOLUMES/ALL YEARS

	 PPC
	  	$[***]
	 POP
	  	$[***]
	 Clinician Programmers
	  	$[***]
	 Patient Feedback Tool
	  	$[***]
	 EPG
	  	$[***]
	 Charging Paddle
	  	$[***]

  
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS
OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 GMM Externals Pricing 

 

											
	 	  	 PPC

	 Annual Volume
	  	 2016
	  	 2017
	  	 2018
	  	 2019
	  	 2020

	[***]	  	$[***]	  	$[***]	  	$[***]	  	$[***]	  	$[***]
	[***]	  	$[***]	  	$[***]	  	$[***]	  	$[***]	  	$[***]
	[***]	  	$[***]	  	$[***]	  	$[***]	  	$[***]	  	$[***]
	[***]	  	$[***]	  	$[***]	  	$[***]	  	$[***]	  	$[***]
	[***]	  	$[***]	  	$[***]	  	$[***]	  	$[***]	  	$[***]
	[***]	  	$[***]	  	$[***]	  	$[***]	  	$[***]	  	$[***]
	[***]	  	$[***]	  	$[***]	  	$[***]	  	$[***]	  	$[***]
	[***]+	  	$[***]	  	$[***]	  	$[***]	  	$[***]	  	$[***]

  

											
	 	  	 POP

	 Annual Volume
	  	 2016
	  	 2017
	  	 2018
	  	 2019
	  	 2020

	[***]	  	$[***]	  	$[***]	  	$[***]	  	$[***]	  	$[***]
	[***]	  	$[***]	  	$[***]	  	$[***]	  	$[***]	  	$[***]
	[***]	  	$[***]	  	$[***]	  	$[***]	  	$[***]	  	$[***]
	[***]	  	$[***]	  	$[***]	  	$[***]	  	$[***]	  	$[***]
	[***]	  	$[***]	  	$[***]	  	$[***]	  	$[***]	  	$[***]
	[***]	  	$[***]	  	$[***]	  	$[***]	  	$[***]	  	$[***]
	[***]	  	$[***]	  	$[***]	  	$[***]	  	$[***]	  	$[***]
	[***]+	  	$[***]	  	$[***]	  	$[***]	  	$[***]	  	$[***]

  

			
	 ALL VOLUMES/ALL YEARS

	 Clinician Programmers
	  	$[***]
	 Patient Feedback Tool
	  	$[***]
	 EPG
	  	$[***]
	 Charging Paddle
	  	$[***]

 The parties hereby agree that so long as the specifications of the Pelvistim EPG are materially and substantially similar to
the Specifications of the Algovita EPG (with the exception of the firmware), the price for the Pelvistim EPG will be [***] as the Algovita EPG pricing set forth above; provided, that in the event that the specifications of the Pelvistim EPG are not
materially and substantially similar to the Specifications of the Algovita EPG (with the exception of the firmware), the parties will negotiate in good faith an adjustment to the price of the Pelvistim EPG. The parties hereby agree that so long as
the specifications of the Pelvistim externals (other than the Pelvistim EPG) are materially and substantially similar to the Specifications of the 
  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST.
OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 
Algovita externals (with the exception of the software for such externals), the price for the Pelvistim externals will be [***] as the Algovita externals pricing set forth above; provided, that
in the event that the specifications of the Pelvistim externals (other than the Pelvistim EPG) are not materially and substantially similar to the Specifications of the Algovita externals (with the exception of the software for such externals), the
parties will negotiate in good faith an adjustment to the price of the Pelvistim externals. For purposes of calculating the annual volumes above, the total quantities of the Algovita externals and the Pelvistim externals purchased and delivered in
the relevant calendar year shall be combined. 
 Purchased Components Pricing 

 

					
	 ALL VOLUMES/ALL YEARS
	 
	 Cable
	  	$	[***]	  
	 Tunneling Tool
	  	$	[***]	  
		
	 Accessories
	  	Price	 
	 Anchor (Box of [***]) 5400
	  	 	$[***]	  
	 Trque Wrnch(Box [***]) 5500
	  	 	$[***]	  
	 Port Plug(Box [***]) 5510
	  	 	$[***]	  
	 Needle (St) [***] ea 5300
	  	 	$[***]	  
	 Needle (Lng) [***] ea 5310
	  	 	$[***]	  
	 Passing Elevator 5600
	  	 	$[***]	  
	 Adhesive Anchor 5410
	  	 	$[***]	  
	 Magnet 4900
	  	 	$[***]	  
	 Adhesive Patches 4240
	  	 	$[***]	  
	 Adjustable Belt 4220
	  	 	$[***]	  
	 Prog. Power Cord 4010
	  	 	$[***]	  
	 Trial Stim Pouch 4320
	  	 	$[***]	  

  
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS
OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.EX-10.8

 Exhibit 10.8 

NUVECTRA CORPORATION 

2016 EQUITY INCENTIVE PLAN 
  

	1	PURPOSE 

 The name of this plan is the Nuvectra Corporation 2016 Equity Incentive
Plan (as it may be amended from time to time, the “Plan”). This Plan was adopted by the Board of Managers of QiG Group, LLC in expectation of the Spin-off (as defined below) and QiG Group, LLC’s conversion from a Delaware limited
liability company to a Delaware corporation with the name of Nuvectra Corporation (“Nuvectra”) and approved by Greatbatch Ltd., as sole member of QiG Group, LLC, effective as of
                    , 2016 (the “Effective Date”). 

The purpose of this Plan is to promote the interests of Nuvectra (together with its Subsidiaries, the “Company”), and its
stockholders by providing officers, other employees, non-employee directors and non-employee consultants and service providers of the Company with appropriate incentives and rewards to encourage them to enter into or continue in service to the
Company and to acquire a proprietary interest in the long-term success of the Company, while aligning the interests of those officers, other employees, non-employee directors and non-employee consultants and service providers with the interests of
the stockholders. 
 The Plan also governs the terms of Incentive Awards granted pursuant to the terms of the Employee Matters Agreement
(“Spin-off Awards”) to current and former employees, directors or service providers of Greatbatch, Inc. (“Greatbatch”) or any of its subsidiaries in connection with the Spin-off. 

 

	2	DEFINITIONS 

 As used in the Plan, the following definitions apply to the terms
indicated below: 
 (a) “Award Agreement” shall mean the written agreement between the Company and a Participant or other document
approved by the Committee evidencing an Incentive Award. 
 (b) “Board of Directors” shall mean the Board of Directors of
Nuvectra. 
 (c) “Cause,” and the term “for Cause” shall mean, 

(1) with respect to a Participant who is a party to a written employment agreement with the Company, which agreement contains a definition of
“for cause” or “cause” (or words of like import) for purposes of termination of employment thereunder by the Company, “for cause” or “cause” as defined in the most recent of such agreements, or 

(2) in all other cases, (i) with respect to a Participant, other than a non-employee director, a determination by the Committee, in its
sole discretion, that one or more of the following has occurred: (A) any intentional or willful failure, or failure due to bad faith, by such Participant to substantially perform his or her duties to the Company that shall not have been
corrected within thirty (30) days following written notice thereof from the Company, (B) any misconduct by such Participant that is significantly injurious to the Company, (C) any breach by such Participant of any covenant contained
in a written agreement between the Participant and the Company, including, for avoidance of doubt, an Award Agreement or other instrument pursuant to which an Incentive Award is granted, (D) such Participant’s conviction of, or entry of a
plea of guilty or nolo contendere in respect of, any felony that results in, or is reasonably expected to result in, economic or reputational injury to the Company or 

 
(E) any material violation of state or federal securities laws or (ii) with respect to a Participant that is a non-employee director, a determination by a majority of the disinterested
members of the Board of Directors, in their sole discretion, that that one or more of the following has occurred: (A) any intentional or willful failure, or failure due to bad faith, by such non-employee director to substantially perform his or
her duties to the Company that shall not have been corrected within thirty (30) days following written notice thereof from the Company, (B) any misconduct by such non-employee director that is significantly injurious to the Company,
(C) any breach by such non-employee director of any covenant contained in an Award Agreement or other instrument pursuant to which an Incentive Award is granted, (D) such non-employee director’s conviction of, or entry of a plea of
guilty or nolo contendere in respect of, any felony that results in, or is reasonably expected to result in, economic or reputational injury to the Company or (E) any material violation of state or federal securities laws. 

(d) “Change in Control” occurs if 

(1) any “Person” or related “Group” of Persons (as such terms are used in Sections 13(d) and 14(d)(2) of the Exchange
Act), is or becomes the “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of more than 50% of the total combined voting power of all classes of capital stock of Nuvectra normally entitled to vote
for the election of directors of Nuvectra; 
 (2) a sale of all or substantially all of the assets of the Company is consummated, in one
transaction or a series of related transactions; 
 (3) any merger or consolidation of Nuvectra is consummated in which the stockholders of
Nuvectra immediately prior to such transaction own, in the aggregate, less than 50% of the total combined voting power of all classes of capital stock of the surviving entity normally entitled to vote for the election of directors of such surviving
entity; 
 (4) approval by the Company’s stockholders of a liquidation or dissolution of the Company; or 

(5) a majority of the members of the Board of Directors are replaced during any one-year period by directors whose appointment or election was
not endorsed by a majority of the members of the Board of Directors as of immediately prior to the date of such appointment or election. 

For purposes hereof, ownership of voting securities shall take into account and shall include ownership as determined by applying the
provisions of Rule 13d-3(d)(1)(i) (as in effect on the date hereof) pursuant to the Exchange Act. In addition, notwithstanding the foregoing, the Spin-off shall not constitute a Change in Control for purposes of the Plan. In addition,
notwithstanding anything in the Plan to the contrary, to the extent an amount forming all or a portion of an Incentive Award represents deferred compensation under Section 409A of the Code that becomes payable upon the occurrence of a Change in
Control, a “Change in Control” will not be considered to have occurred unless the event constitutes a change in control event under Section 409A of the Code. 

(e) “Code” shall mean the Internal Revenue Code of 1986, as it may be amended from time to time. Any reference to a section of the
Code shall be deemed to include a reference to any applicable regulations promulgated thereunder. 
 (f) “Committee” shall mean
the Compensation and Organization Committee of the Board of Directors or such other committee as the Board of Directors shall appoint from time to time to administer the Plan; provided, that the Committee shall at all times consist of two or more
persons, each of whom shall be a member of the Board of Directors and an “independent director” under the rules of any 

  
 2 

 
securities exchange on which the Company Stock is listed, quoted or traded. To the extent required for transactions under the Plan to qualify for the exemptions available under Rule 16b-3 (as
defined herein), members of the Committee (or any subcommittee thereof) shall be “non-employee directors” within the meaning of Rule 16b-3. To the extent required for compensation realized from Incentive Awards (as defined herein) under
the Plan to be deductible by the Company pursuant to Section 162(m) of the Code, members of the Committee (or any subcommittee thereof) shall be “outside directors” within the meaning of Section 162(m) of the Code. 

(g) “Company Stock” shall mean the common stock, par value $0.001 per share, of Nuvectra. 

(h) “Covered Employee” means a Participant who is, or could be, a “covered employee” within the meaning of
Section 162(m) of the Code. 
 (i) “Disability,” unless otherwise provided in an Award Agreement, shall mean 

(1) with respect to a Participant who is a party to a written employment agreement with the Company that contains a definition of
“disability” or “permanent disability” (or words of like import) for purposes of termination of employment thereunder by the Company, “disability” or “permanent disability” as defined in the most recent of
such agreements, or 
 (2) in all other cases, means such Participant’s inability to perform substantially his or her duties to the
Company by reason of physical or mental illness, injury, infirmity or condition: (A) for a continuous period for 180 days or one or more periods aggregating 180 days in any twelve-month period; (B) at such time as such Participant is
eligible to receive disability income payments under any long-term disability insurance plan maintained by the Company; or (C) at such earlier time as such Participant or the Company submits medical evidence, in the form of a physician’s
certification, that such Participant has a physical or mental illness, injury, infirmity or condition that will likely prevent such Participant from substantially performing his duties for 180 days or longer. 

(j) “Employee Matters Agreement” shall mean that certain employee matters agreement entered into between Greatbatch and Nuvectra in
connection with the Spin-off. 
 (k) “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended. 

(l) “Fair Market Value” means, for any particular date, (i) for any period during which the Company Stock shall be
(A) listed for trading on a national securities exchange, including, without limitation, the New York Stock Exchange or the NASDAQ Stock Market, (B) listed for trading on a national market system or (C) listed, quoted or traded on any
automated quotation system, the closing price per share of Company Stock on such exchange or system as of the close of such trading day as reported in The Wall Street Journal or such other source as the Committee deems reliable, or
(ii) the market price per share of Company Stock as determined in good faith by the Committee in the event (i) above shall not be applicable. If the Fair Market Value is to be determined as of a day when the securities markets are not
open, the Fair Market Value on that day shall be the Fair Market Value on the first prior preceding day when the markets were open. 
 (m)
“Grant Date” shall mean the date or event specified by the Committee on which a grant of an Incentive Award will become effective (which date with respect to an Option or SAR will not be earlier than the date on which the Committee takes
action with respect thereto), and, with respect to any Spin-off Award, shall mean the date the corresponding Greatbatch equity incentive award was originally granted. 

  
 3 

 (n) “Incentive Award” shall mean an Option, SAR, share of Restricted Stock, Restricted
Stock Unit or Stock Bonus (each as defined herein) granted pursuant to the terms of the Plan, including any Spin-off Award. 
 (o)
“Incentive Stock Option” shall mean an Option that is an “incentive stock option” within the meaning of Section 422 of the Code. 

(p) “Non-Qualified Stock Option” shall mean an Option that is not an Incentive Stock Option. 

(q) “Option” shall mean an option to purchase shares of Company Stock granted pursuant to Section 7. 

(r) “Participant” shall mean an employee, a non-employee consultant or service provider, or non-employee director of the Company to
whom an Incentive Award is granted pursuant to the Plan and, upon his or her death, his or her successors, heirs, executors and administrators, as the case may be. Participant shall also include persons entitled to receive Incentive Awards pursuant
to the operation of the Employee Matters Agreement to whom a Spin-off Award has been made under the Plan. 
 (s) “Performance-Based
Award” means an Incentive Award granted to selected Covered Employees pursuant to Sections 7, 8, 9 or 10, but which is subject to the terms and conditions set forth in Section 12. All Performance-Based Awards are intended to qualify as
Qualified Performance-Based Compensation. 
 (t) “Performance Criteria” means the criteria that the Committee selects for purposes
of establishing the Performance Goal or Performance Goals for a Participant for a Performance Period. The Performance Criteria that will be used to establish Performance Goals are limited to the following: (i) net earnings or net income (either
before or after one or more of the following: interest, taxes, depreciation, amortization and non-cash equity-based compensation expenses), (ii) economic value-added (as determined by the Committee), (iii) sales or revenue, (iv) net
earnings or net income (either before or after taxes), (v) operating earnings or income, (vi) cash flow (including, but not limited to, operating cash flow and free cash flow), (vii) gross profit or gross profit growth,
(viii) cash flow return on capital, (ix) return on investment, (x) return on stockholders’ equity, (xi) return on assets or net assets, (xii) return on capital, (xiii) stockholder returns, (xiv) return on
sales, (xv) gross or net profit margin, (xvi) productivity, (xvii) expenses or expense targets, (xviii) margins, (xix) improvement of capital structure, (xx) operating efficiency, (xxi) cost reduction or savings,
(xxii) budget and expense management, (xxiii) customer satisfaction, (xxiv) working capital, (xxv) basic or diluted earnings or loss per share (before or after taxes), (xxvi) price per share of Company Stock (including, but
not limited to growth measures or total stockholder return), (xxvii) completion of acquisitions or business expansion, (xxviii) regulatory achievements or compliance (including, without limitation, regulatory body approval for
commercialization of a product), (xxix) implementation or completion of critical products, (xxx) enterprise value, (xxxi) attainment of objective employee metrics or (xxxii) market share, any of which may be measured either in
absolute terms or as compared to any incremental increase or as compared to results of a market index, group of other companies or a combination thereof. The Committee shall, within the time prescribed by Section 162(m) of the Code, define in
an objective fashion the manner of calculating the Performance Criteria it selects to use for such Performance Period for such Participant. 

(u) “Performance Goals” means, for a Performance Period, the one or more goals established in writing by the Committee for the
Performance Period based upon the Performance Criteria. Depending on the Performance Criteria used to establish such Performance Goals, the Performance Goals may be expressed in terms of overall Company performance or the performance of a division,
business unit, 

  
 4 

 
operational unit or an individual. The Performance Goals may be subject to a threshold level of performance below which no payment will be made or no vesting will occur, levels of performance at
which specified payments will be made or specified vesting will occur, and a maximum level of performance above which no additional payment will be made or no vesting will occur. To the extent consistent with Section 162(m) of the Code, the
Committee, in its sole discretion, may adjust or modify the calculation of Performance Goals for such Performance Period in order to prevent the dilution or enlargement of the rights of Participants (i) in the event of, or in anticipation of,
any unusual or extraordinary corporate item, transaction, event, or development, (ii) in recognition of, or in anticipation of, any other unusual or nonrecurring events affecting the Company (determined consistent with U.S. generally accepted
accounting principles), or the financial statements of the Company, or (iii) in response to, or in anticipation of, changes in applicable laws (including, without limitation, tax laws), regulations, accounting principles, or business
conditions. 
 (v) “Performance Period” means the one or more periods of time, which may be of varying and overlapping durations,
as the Committee may select, over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Participant’s right to, and the payment of, a Performance-Based Award. 

(w) “Qualified Performance-Based Compensation” means any compensation that is intended to qualify as “qualified
performance-based compensation” as described in Section 162(m)(4)(C) of the Code. 
 (x) “Reprice” shall mean
(A) changing the terms of an Incentive Award to lower its exercise price; (B) any other action that is treated as a “repricing” under generally accepted accounting principles; and (C) repurchasing for cash or canceling an
Incentive Award at a time when its exercise price is greater than the Fair Market Value of the underlying stock in exchange for another Incentive Award, unless the cancellation and exchange occurs in connection with a Change in Control. Such
cancellation and exchange would be considered a Repricing regardless of whether it is treated as a “repricing” under generally accepted accounting principles and regardless of whether it is voluntary on the part of the Participant. 

(y) A share of “Restricted Stock” shall mean a share of Company Stock that is granted pursuant to the terms of Section 9 hereof
and that is subject to the restrictions set forth in Section 9(c). 
 (z) “Restricted Stock Unit” means a contractual right
to receive a share of Company Stock in the future that is granted pursuant to the terms of Section 10. 
 (aa) “Rule 16b-3”
shall mean the rule thus designated as promulgated under the Exchange Act. 
 (bb) “SAR” shall mean a stock appreciation right
granted pursuant to Section 8. 
 (cc) “Spin-off” shall mean the spin-off of the Company from Greatbatch into an independent,
publicly-traded company, effective as of                      , 2016. 

(dd) “Stock Bonus” shall mean a bonus payable in shares of Company Stock or a payment made in shares of Company Stock pursuant to a
deferred compensation plan of the Company. 
 (ee) “Subsidiary” shall mean any corporation or other entity in which, at the time
of reference, the Company owns, directly or indirectly, stock or similar interests comprising more than fifty (50) percent of the combined voting power of all outstanding securities of such entity. 

  
 5 

 (ff) “Vesting Date” shall mean the date established by the Committee on which a share
of Restricted Stock or Restricted Stock Unit may vest. 
  

	3	STOCK SUBJECT TO THE PLAN 

 (a) Company Stock Available for Incentive Awards 

The total number of shares of Company Stock reserved for issuance under the Plan shall not exceed
(i)              shares (the “Share Limit”), and (ii) an additional number of shares of Company Stock equal to the number of shares of Company Stock subject to all
Spin-off Awards outstanding immediately following the Spin-off. Such shares may be authorized but unissued Company Stock or authorized and issued Company Stock held in the Company’s treasury or acquired by the Company for the purposes of the
Plan. The Committee may direct that any stock certificate evidencing shares issued pursuant to the Plan shall bear a legend setting forth such restrictions on transferability as may apply to such shares pursuant to the Plan. 

(b) Automatic Share Limit Increase 

The Share Limit will automatically increase on January 1st of each year, for nine (9) years following the Effective Date, in an
amount equal to four (4%) percent of the total number of shares of Company Stock outstanding on December 31st of the preceding year. The Committee may act prior to January 1st of a given year to provide that there will be no
January 1st increase of the Share Limit for such year or that the increase in the Share Limit for such year will be a smaller number of shares of Company Stock than would otherwise occur pursuant to the preceding sentence. 

(c) Total Grants by Award Type 

Excluding any Spin-off Awards, the aggregate number of shares of Company Stock to be awarded under the Plan as Incentive Stock Options shall
not exceed              shares. Any shares of Company Stock added to the Share Limit pursuant to Section 3(b) hereof shall be available for issuance as Incentive Stock Options only to
the extent that making such shares of Company available for issuance as Incentive Stock Options would not cause any Incentive Stock Option to cease to qualify as such. With respect to SARs, when a stock settled SAR is exercised, the shares subject
to a SAR grant agreement shall be counted against the Share Limit as one (1) share for every share subject thereto, regardless of the number of shares used to settle the SAR upon exercise. 

(d) Non-Employee Director Limitation 

Excluding any Spin-off Awards, the maximum number of shares of Company Stock subject to Incentive Awards awarded during any fiscal year to a
non-employee director, taken together with any cash fees paid to such non-employee director during the fiscal year, shall not exceed $500,000 in total value (calculating the value of any such Incentive Awards based on the grant date fair value of
such Incentive Awards for financial reporting purposes). 
 (e) Employee Limitation 

Excluding any Spin-off Awards, the aggregate number of shares of Company Stock subject to (i) Options and SARs awarded to any one
employee during any fiscal year of the Company, including awards made pursuant to Section 12, shall not exceed              shares and (ii) Incentive Awards, other than Options
and SARs, awarded to any one employee during any fiscal year of the Company shall not exceed              shares. Determinations under the preceding sentence shall be made in a manner

  
 6 

 
that is consistent with Section 162(m) of the Code and regulations promulgated thereunder. The provisions of this Section 3(e) shall not apply in any circumstance with respect to which
the Committee determines that compliance with Section 162(m) of the Code is not necessary. 
 (f) Adjustment for Change in
Capitalization 
 If there is any change in the outstanding shares of Company Stock by reason of a stock dividend or distribution, stock
split-up, recapitalization, combination or exchange of shares, or by reason of any merger, consolidation, spinoff or other corporate reorganization in which the Company is the surviving corporation, the number of shares available for issuance both
in the aggregate and with respect to each outstanding Incentive Award, the price per share under each outstanding Incentive Award, and the limitations set forth in Sections 3(c), (d) and (e), will be proportionately adjusted by the Committee,
whose determination shall be final and binding. After any adjustment made pursuant to this Section 3(f), the number of shares subject to each outstanding Incentive Award shall be rounded to the nearest whole number. 

(g) Other Adjustments 
 In the
event of any transaction or event described in Section 3(f) or any unusual or nonrecurring transactions or events affecting the Company, any affiliate of the Company, or the financial statements of the Company or any affiliate of the Company
(including, without limitation, any Change in Control), or of changes in applicable laws, regulations or accounting principles, and whenever the Committee determines that action is appropriate in order to preserve the economic intent with respect to
any Incentive Award under the Plan, to prevent the dilution or enlargement of the benefits or potential benefits intended to be made available under the Plan or with respect to any Incentive Award under the Plan, to facilitate such transactions or
events or to give effect to such changes in laws, regulations or principles, the Committee, in its sole discretion and on such terms and conditions as it deems appropriate, including, if the Committee deems appropriate, the principles of Treasury
Regulation Section 1.424-1(a)(5) except to the extent necessary to ensure that the action does not violate Section 409A of the Code, either by amendment of the terms of any outstanding Incentive Awards or by action taken prior to the
occurrence of such transaction or event, is hereby authorized to take any one or more of the following actions: 
 (i) To
provide for either (A) termination of any such Incentive Award in exchange for an amount of cash and/or other property, if any, equal to the amount that would have been attained upon the exercise of such Incentive Award or realization of the
Participant’s rights (and, for the avoidance of doubt, if as of the date of the occurrence of the transaction or event described in this Section 3(g) the Committee determines in good faith that no amount would have been attained upon the
exercise of such Incentive Award or realization of the Participant’s rights, then such Incentive Award may be terminated by the Company without payment) or (B) the replacement of such Incentive Award with other rights or property selected
by the Committee in its sole discretion; 
 (ii) To provide that such Incentive Award be assumed by the successor or survivor
corporation, or a parent or subsidiary thereof, or shall be substituted for by similar options, rights or awards covering the stock of the successor or survivor corporation, or a parent or subsidiary thereof, with appropriate adjustments as to the
number and kind of shares and prices; and 
 (iii) To make adjustments in the number and type of shares of Company Stock (or
other securities or property) subject to outstanding Incentive Awards, and in the number and kind of outstanding Restricted Stock and/or in the terms and conditions of (including the grant or exercise price), and the criteria included in,
outstanding options, rights and awards and options, rights and awards which may be granted in the future; 

  
 7 

 (iv) To provide that such Incentive Award shall be exercisable or payable or
fully vested with respect to all shares covered thereby, notwithstanding anything to the contrary in the Plan or the applicable Award Agreement; and 

(v) To provide that the Incentive Award cannot vest, be exercised or become payable after such event. 

(h) Re-use of Shares 
 Other
than with respect to any Spin-off Award, the aggregate number of shares of Company Stock issued under the Plan at any time shall equal only the number of shares of Company stock actually issued upon exercise or settlement of an Incentive Award.
Other than with respect to any Spin-off Award, if an Incentive Award terminates, expires, is cancelled, forfeited, or lapses for any reason, any shares of Company Stock subject to the Incentive Award shall again be available for the grant of an
Incentive Award pursuant to the Plan. Shares of Company Stock that are (i) used to pay the exercise price of an Option, (ii) delivered or withheld to satisfy tax withholding obligations with respect to an Incentive Award,
(iii) covered by a stock-settled SAR that are not issued upon settlement of such SAR or (iv) not issued because cash (other than with respect to fractional shares) is issued in lieu of such shares of Company Stock pursuant to an Incentive
Award will, in each case, not be available for further grants of Incentive Awards pursuant to the Plan. To the extent permitted by applicable law or any stock exchange rule, shares of Company Stock issued in assumption of, or in substitution for,
any outstanding awards of any entity acquired in any form of combination by the Company or any Subsidiary shall not be counted towards the Share Limit and shall be available for grant pursuant to this Plan. 

(i) No Repricing 
 Absent
stockholder approval, neither the Committee nor the Board of Directors shall have any authority, with or without the consent of the affected holders of Incentive Awards, to Reprice an Incentive Award; provided, however, that nothing in this
Section 3(i) shall be construed to apply to the issuance of an Incentive Award that is a Spin-off Award, or the issuance of an Incentive Award in connection with the acquisition by the Company of an unrelated entity. This paragraph may not be
amended, altered or repealed by the Board of Directors or the Committee without approval of the stockholders of the Company. 
 (j) Vesting
Limitation on Restricted Stock and Restricted Stock Unit Awards. 
 Any Restricted Stock or Restricted Stock Unit Incentive Award (other
than any Spin-off Awards) that vests solely on the basis of the passage of time (e.g., not on the basis of achievement of Performance Goals) shall not fully vest more quickly than over the three year period beginning on the Grant Date. Any
Restricted Stock or Restricted Stock Unit Performance-Based Awards (other than any Spin-off Awards) shall not vest prior to the first anniversary of the Grant Date. Notwithstanding anything to the contrary in this Section 3(j): (i) the
Committee may provide that such vesting restrictions may lapse or be waived upon the Participant’s death, Disability or termination of service, or upon a Change of Control, (ii) Incentive Awards that result in the issuance of an aggregate
of up to five percent (5%) of the Share Limit (as may be adjusted as provided under the terms of the Plan) may be granted to any one or more Participants without respect to such minimal vesting provisions, and (iii) the minimal vesting
restrictions shall not apply to any Incentive Award made to any member of the Board of Directors as a component of the payment for his or her service on the Board of Directors. 

  
 8 

	4	ADMINISTRATION OF THE PLAN 

 The Plan shall be administered by the Committee. The
Committee shall from time to time designate the persons who shall be granted Incentive Awards and the amount, type and other features of each Incentive Award. 

The Committee shall have full authority to administer the Plan, including authority to interpret and construe any provision of the Plan and
the terms of any Award Agreement or any Incentive Award issued under it and to adopt such rules and regulations for administering the Plan as it may deem necessary or appropriate. The Committee shall determine whether an authorized leave of absence
or absence due to military or government service shall constitute termination of employment. The determination of whether an individual has a Disability shall be made by the Committee. Decisions of the Committee shall be final and binding on all
Participants. Determinations made by the Committee under the Plan need not be uniform but may be made on a Participant-by-Participant basis. Notwithstanding anything to the contrary contained herein, the Board of Directors may, in its sole
discretion, at any time and from time to time, resolve to administer the Plan, in which case the term “Committee” as used herein shall be deemed to mean the Board of Directors. 

The Committee may, in its absolute discretion, without amendment to the Plan, (i) accelerate the date on which any Option or SAR granted
under the Plan becomes exercisable, (ii) waive or amend the operation of Plan provisions respecting exercise after termination of service or otherwise adjust any of the terms of such Option or SAR and (iii) accelerate the Vesting Date, or
waive any condition imposed hereunder, with respect to any share of Restricted Stock or Restricted Stock Unit or otherwise adjust any of the terms applicable to such share. 

No member of the Committee shall be liable for any action, omission or determination relating to the Plan, and the Company shall indemnify and
hold harmless each member of the Committee and each other director or employee of the Company to whom any duty or power relating to the administration or interpretation of the Plan has been delegated against any cost or expense (including counsel
fees and expenses) or liability (including any sum paid in settlement of a claim with the approval of the Board of Directors, which approval shall not be unreasonably withheld or delayed) arising out of any action, omission or determination relating
to the Plan, unless, in either case, such action, omission or determination was taken or made by such member, director or employee in bad faith and without reasonable belief that it was in the best interests of the Company. 

 

	5	ELIGIBILITY 

 The persons who shall be eligible to receive Incentive Awards under
the Plan shall be such employees of the Company (including (i) employees who are also directors and (ii) prospective employees conditioned on their becoming employees), non-employee consultants or service providers, and non-employee
directors of the Company as the Committee shall designate from time to time. In addition, persons entitled to receive Incentive Awards pursuant to the operation of the Employee Matters Agreement shall be eligible to receive Spin-off Awards under the
Plan. 
  

	6	AWARDS UNDER THE PLAN; AWARD AGREEMENTS 

 The Committee may grant Options, SARs,
shares of Restricted Stock, Restricted Stock Units and Stock Bonuses, in such amounts and with such terms and conditions as the Committee shall determine, subject to the provisions of the Plan. 

  
 9 

 Each Incentive Award granted under the Plan (except an unconditional Stock Bonus) shall be
evidenced by an Award Agreement, which shall contain such provisions as the Committee may in its sole discretion deem necessary or desirable. By accepting an Incentive Award, a Participant thereby agrees that the Incentive Award shall be subject to
all of the terms and provisions of the Plan and the applicable Award Agreement. 
  

	7	OPTIONS 

 (a) Identification of Options 

Each Option shall be clearly identified in the applicable Award Agreement as either an Incentive Stock Option or a Non-Qualified Stock Option.
In the absence of such identification, an Option will be deemed to be a Non-Qualified Stock Option. 
 (b) Exercise Price 

Each Award Agreement with respect to an Option shall set forth the amount (the “Exercise Price”) payable by the holder to the
Company upon exercise of the Option. The Exercise Price for an Option shall be determined by the Committee but shall in no event be less than one hundred percent (100%) of the Fair Market Value of a share of Company Stock on the Grant Date.

 (c) Term and Exercise of Options 

(1) The applicable Award Agreement will provide the date or dates on which an Option shall become exercisable. The Committee shall determine
the expiration date of each Option; provided, however, that no Option shall be exercisable more than ten (10) years after the Grant Date. Unless the applicable Award Agreement provides otherwise, no Option (other than any Spin-off Awards) shall
be exercisable prior to the first anniversary of the Grant Date. 
 (2) An Option may be exercised for all or any portion of the shares as
to which it is exercisable; provided, that no partial exercise of an Option shall be for an aggregate exercise price of less than $1,000. The partial exercise of an Option shall not cause the expiration, termination or cancellation of the remaining
portion thereof. 
 (3) Unless the Committee determines otherwise, an Option shall be exercised by delivering notice to the Company’s
principal office, to the attention of its Secretary (or the Secretary’s designee), no less than one nor more than ten (10) business days in advance of the effective date of the proposed exercise. Such notice shall specify the number of
shares of Company Stock with respect to which the Option is being exercised and the effective date of the proposed exercise and shall be signed by the Participant or other person then having the right to exercise the Option. Payment for shares of
Company Stock purchased upon the exercise of an Option shall be made on the effective date of such exercise by one or a combination of the following means: (i) in cash, by certified check, bank cashier’s check or wire transfer;
(ii) subject to the approval of the Committee, in shares of Company Stock owned by the Participant for at least six months prior to the date of exercise and valued at their Fair Market Value on the effective date of such exercise; or
(iii) by means of a broker assisted cashless exercise procedure complying with applicable law, and (iv) by such other provision as the Committee may from time to time authorize. Any payment in shares of Company Stock shall be effected by
the delivery of such shares to the Secretary (or the Secretary’s designee) of the Company, duly endorsed in blank or accompanied by stock powers duly executed in blank, together with any other documents and evidences as the Secretary (or the
Secretary’s designee) of the Company shall require. 

  
 10 

 (4) Stock certificates for shares of Company Stock purchased upon the exercise of an Option shall
be issued in the name of the Participant or other person entitled to receive such shares, and delivered to the Participant or such other person reasonably promptly following the effective date on which the Option is exercised. 

(d) Limitations on Incentive Stock Options 

(1) Incentive Stock Options may be granted only to employees of the Company or any “subsidiary corporation” thereof (within the
meaning of Section 424(f) of the Code and the applicable regulations thereunder). 
 (2) To the extent that the aggregate Fair Market
Value of shares of Company Stock with respect to which Incentive Stock Options are exercisable for the first time by a Participant during any calendar year under the Plan and any other stock option plan of the Company (or any “subsidiary
corporation” of the Company within the meaning of Section 424 of the Code) shall exceed $100,000, or such higher value as may be permitted under Section 422 of the Code, such Options shall be treated as Non-Qualified Stock Options to
the extent required by Section 422 of the Code. Such Fair Market Value shall be determined as of the Grant Date on which each such Incentive Stock Option is granted. 

(3) No Incentive Stock Option may be granted to an individual if, at the time of the grant, such individual owns stock possessing more than
10% of the total combined voting power of all classes of stock of the Company (or any “subsidiary corporation” of the Company within the meaning of Section 424 of the Code), unless (i) the exercise price of such Incentive Stock
Option is at least 110% of the Fair Market Value of a share of Company Stock at the time such Incentive Stock Option is granted and (ii) such Incentive Stock Option (other than any Spin-off Awards) is not exercisable after the expiration of
five years from the Grant Date on which such Incentive Stock Option is granted. 
 (e) Effect of Termination of Employment 

(1) Unless the applicable Award Agreement provides or the Committee shall determine otherwise, in the event that the employment of a
Participant with the Company shall terminate for any reason other than for Cause, on account of Disability of the Participant or death of the Participant: (i) Options granted to such Participant, to the extent that they were exercisable at the
time of such termination, shall remain exercisable until the date that is three (3) months after such termination, on which date they shall expire; and (ii) Options granted to such Participant, to the extent that they were not exercisable
at the time of such termination, shall expire at the close of business on the date of such termination. The three-month period described in this Section 7(e)(1) shall be extended to one year in the event of the Participant’s death during
such three-month period. Notwithstanding the foregoing, no Option shall be exercisable after the expiration of its term. 
 (2) Unless the
applicable Award Agreement provides or the Committee shall determine otherwise, in the event that the employment of a Participant with the Company shall terminate on account of the Disability or death of the Participant: (i) Options granted to
such Participant, to the extent that they were exercisable at the time of such termination, shall remain exercisable until the first anniversary of such termination, on which date they shall expire; and (ii) Options granted to such Participant,
to the extent that they were not exercisable at the time of such termination, shall expire at the close of business on the date of such termination. Notwithstanding the foregoing, no Option shall be exercisable after the expiration of its term. 

  
 11 

 (3) In the event of the termination of a Participant’s employment for Cause, all outstanding
Options granted to such Participant shall cease to be exercisable, if applicable, and expire at the commencement of business on the date of such termination. 

(f) Acceleration of Exercise Date Upon Change in Control 

Upon the occurrence of a Change in Control, each Option granted under the Plan and outstanding at such time shall become fully and immediately
exercisable and shall remain exercisable until its expiration, termination or cancellation pursuant to the terms of the Plan. In addition, in the event of a Change in Control, the Committee may in its discretion, cancel any outstanding Options and
pay to the holders thereof, in cash or stock, or any combination thereof, the value of such Options based upon the price per share of Company Stock to be received by other stockholders of the Company in the Change in Control less the Exercise Price
of each Option. Additionally, in the event of a Change of Control, with respect to any Option with an Exercise Price that equals or exceeds the price per share of Common Stock to be received by the other stockholders of the Company in the Change in
Control, the Committee may in its discretion, cancel any outstanding Option without payment of consideration therefor. 
 (g)
Transferability of Option 
 Except as otherwise provided in an applicable Award Agreement, during the lifetime of a Participant each Option
granted to a Participant shall be exercisable only by the Participant and no Option shall be assignable or transferable otherwise than by will or by the laws of descent and distribution. The Committee may in its sole discretion on a case by case
basis, in any applicable agreement evidencing an Option (other than, to the extent inconsistent with the requirements of Section 422 of the Code applicable to Incentive Stock Options), permit a Participant to transfer all or some of the Options
to (i) the Participant’s Immediate Family Members, or (ii) a trust or trusts for the exclusive benefit of such Immediate Family Members. Following any such transfer, any transferred Options shall continue to be subject to the same
terms and conditions as were applicable immediately prior to the transfer. “Immediate Family Members” shall mean a Participant’s spouse, child(ren) and grandchild(ren). Notwithstanding the foregoing, Non-Qualified Stock Options may be
transferred to a Participant’s former spouse pursuant to a property settlement made part of an agreement or court order incident to the divorce. 
  

	8	SARS 

 (a) Exercise Price 

The exercise price per share of a SAR shall be determined by the Committee at the time of grant, but shall in no event be less than one
hundred percent (100%) of the Fair Market Value of a share of Company Stock on the Grant Date. 
 (b) Benefit Upon Exercise 

The exercise of SARs with respect to any number of shares of Company Stock shall entitle the Participant to receive unrestricted, fully
transferable shares of Company Stock, which shall be issued reasonably promptly after the date on which the SARs are exercised, equal in value to the number of SARs exercised multiplied by (i) the Fair Market Value of a share of Company Stock
on the exercise date over (ii) the exercise price of the SAR. Any fractional share amounts shall be settled in cash. Notwithstanding the foregoing, shares of Company Stock issued may be subject to restrictions on transfer as a result of
applicable securities laws or pursuant to Section 15. 

  
 12 

 (c) Term and Exercise of SARS 

(1) The applicable Award Agreement will provide the dates or dates on which a SAR shall become exercisable. The Committee shall determine the
expiration date of each SAR; provided, however, that no SAR shall be exercisable more than ten (10) years after the Grant Date. Unless the applicable Award Agreement provides otherwise, no SAR shall be exercisable prior to the first anniversary
of the Grant Date. 
 (2) A SAR may be exercised for all or any portion of the shares as to which it is exercisable; provided, that no
partial exercise of a SAR shall be for an aggregate exercise price of less than $1,000. The partial exercise of a SAR shall not cause the expiration, termination or cancellation of the remaining portion thereof. 

(3) Unless the Committee determines otherwise, a SAR shall be exercised by delivering notice to the Company’s principal office, to the
attention of its Secretary (or the Secretary’s designee), no less than one nor more than ten (10) business days in advance of the effective date of the proposed exercise. Such notice shall specify the number of shares of Company Stock with
respect to which the SAR is being exercised, and the effective date of the proposed exercise, and shall be signed by the Participant. 
 (d)
Effect of Termination of Employment 
 The provisions set forth in Section 7(e) with respect to the exercise of Options following
termination of employment shall apply as well to such exercise of SARs. 
 (e) Acceleration of Exercise Date Upon Change in Control 

Upon the occurrence of a Change in Control, any SAR granted under the Plan and outstanding at such time shall become fully and immediately
exercisable and shall remain exercisable until its expiration, termination or cancellation pursuant to the terms of the Plan. In addition, in the event of a Change in Control, the Committee may in its discretion, cancel any outstanding SARs and pay
to the holders thereof, in cash or stock, or any combination thereof, the value of such SARs based upon the price per share of Company Stock to be received by other stockholders of the Company in the Change in Control less the exercise price of each
SAR. Additionally, in the event of a Change of Control, with respect to any SAR with an exercise price that equals or exceeds the price per share of Common Stock to be received by the other stockholders of the Company in the Change in Control, the
Committee may in its discretion, cancel any outstanding SAR without payment of consideration therefor. 
  

	9	RESTRICTED STOCK 

 (a) General and Vesting Date 

Subject to the provisions of Section 3(j) hereof, on a Grant Date of any shares of Restricted Stock, the Committee shall establish a
Vesting Date or Vesting Dates with respect to such shares of Restricted Stock. The Committee may divide such shares of Restricted Stock into classes and assign a different Vesting Date to each class. Reasonably promptly after any shares of
Restricted Stock have been granted, the Company shall cause the specified number of shares of Restricted Stock to be issued in the name of the Participant in accordance with the provisions of Section 9(e). Provided that all conditions to the
vesting of a share of Restricted Stock imposed pursuant to Section 9(b) are satisfied, and except as provided in Section 9(g), upon the occurrence of the Vesting Date with respect to a share of Restricted Stock, such share shall vest and
the restrictions of Section 9(c) shall cease to apply to such share. 

  
 13 

 (b) Conditions to Vesting 

At the time of the grant of shares of Restricted Stock, the Committee may impose such restrictions or conditions to the vesting of such shares
as it, in its sole discretion, deems appropriate. By way of example and not by way of limitation, the Committee may require, as a condition to the vesting of any class or classes of shares of Restricted Stock, that the Participant or the Company
achieves such performance goals as the Committee may specify under Section 12. 
 (c) Restrictions on Transfer Prior to Vesting 

Prior to the vesting of a share of Restricted Stock, no transfer of a Participant’s rights with respect to such share, whether voluntary
or involuntary, by operation of law or otherwise, shall be permitted. Immediately upon any attempt to transfer such rights, such share, and all of the rights related thereto, shall be forfeited by the Participant. 

(d) Rights as Stockholder 
 Upon
issuance of Restricted Stock, the Participant shall have, unless otherwise provided by the Committee, all rights of a stockholder with respect to such shares, subject to any restrictions set forth in an Award Agreement, including the right to
receive any dividend or other distribution with respect to such shares of Restricted Stock. The Committee in its sole discretion may require that any dividends paid on shares of Restricted Stock shall be held in escrow until all restrictions on such
shares have lapsed. 
 (e) Issuance of Certificates 

(1) Reasonably promptly after any shares of Restricted Stock have been granted, the Company shall cause to be issued a stock certificate,
registered in the name of the Participant to whom such shares were granted, evidencing such shares; provided, that the Company shall not cause such a stock certificate to be issued to such Participant unless it has received a stock power duly
endorsed in blank from the Participant with respect to such shares. Each such stock certificate shall bear any such legend as the Committee may determine. Such legend shall not be removed until such shares vest pursuant to the terms hereof. 

(2) Each certificate issued pursuant to this Section 9(e), together with the stock powers relating to the shares of Restricted Stock
evidenced by such certificate, shall be held by the Company in such manner as the Company may determine unless the Committee determines otherwise. 

(f) Consequences of Vesting 

Upon the vesting of a share of Restricted Stock pursuant to the terms of the Plan and the applicable Award Agreement, the restrictions of
Section 9(c) shall cease to apply to such share. Reasonably promptly after a share of Restricted Stock vests, the Company shall cause to be delivered to the Participant to whom such shares were granted, a stock certificate evidencing such
share, free of the legend set forth in Section 9(e). Notwithstanding the foregoing, such share still may be subject to restrictions on transfer as a result of applicable securities laws or pursuant to Section 15. 

(g) Effect of Termination of Employment 

(1) Unless the applicable Award Agreement or the Committee determines otherwise, in the event of the termination of a Participant’s
service to the Company for any reason other than for Cause, all shares of Restricted Stock granted to such Participant which have not vested as of the date of such termination shall immediately be forfeited and returned to the Company. The Committee
also shall have the right to require the return of all dividends paid on such shares, whether by termination of any escrow arrangement under which such dividends are held or otherwise. 

  
 14 

 (2) In the event of the termination of a Participant’s employment for Cause, all shares of
Restricted Stock granted to such Participant which have not vested prior to the date of such termination shall immediately be forfeited and returned to the Company, together with any dividends credited on such shares by termination of any escrow
arrangement under which such dividends are held or otherwise. 
 (h) Effect of Change in Control 

Upon the occurrence of a Change in Control, all outstanding shares of Restricted Stock that have not previously vested shall immediately vest.
In addition, in the event of a Change in Control, the Committee may in its discretion, cancel any outstanding shares of Restricted Stock and pay to the holders thereof, in cash or stock, or any combination thereof, the value of such shares of
Restricted Stock based upon the price per share of Company Stock to be received by other stockholders of the Company in the Change in Control. 
  

	10	RESTRICTED STOCK UNITS  

 (a) Vesting Date 

Subject to the provisions of Section 3(j) hereof, at the time of the grant of Restricted Stock Units, the Committee shall establish a
Vesting Date or Vesting Dates with respect to such Restricted Stock Units. The Committee may divide such Restricted Stock Units into classes and assign a different Vesting Date to each class. Provided that all conditions to the vesting of a
Restricted Stock Unit imposed pursuant to Section 10(c) are satisfied, and except as provided in Section 10(d), upon the occurrence of the Vesting Date with respect to a Restricted Stock Unit, such Restricted Stock Unit shall vest and
shares of Company Stock will be delivered pursuant to Section 10(b). 
 (b) Benefit Upon Vesting 

Upon the vesting of a Restricted Stock Unit, the Participant shall be entitled to receive one unrestricted, fully transferable share of
Company Stock for each Restricted Stock Unit scheduled to be vested on such date and not previously forfeited. Delivery of the share of Company Stock will occur as soon as practicable following the date of vesting or, if otherwise specified in the
applicable Award Agreement, on such later settlement date or dates as specified in the Award Agreement, and a Participant will have only the rights of a general unsecured creditor of the Company with respect to each Restricted Stock Unit until
delivery of the share or payment is made as specified in the Award Agreement. If explicitly provided in the applicable Award Agreement, the Committee may, in its sole discretion, elect to (i) pay cash or (ii) pay part in cash and part in
Company Stock in lieu of delivering only shares of Company Stock in settlement of the Restricted Stock Unit. If a cash payment is made in lieu of delivering shares of Company Stock, the amount of such payment shall be equal to the Fair Market Value
of the Company Stock as of the date on which such Restricted Stock Units vested or, if a later settlement date is specified in the Award Agreement, the Fair Market Value of the Company Stock as of the specified date of settlement. Notwithstanding
the foregoing, shares of Company Stock issued may be subject to restrictions on transfer as a result of applicable securities laws or pursuant to Section 15. 

  
 15 

 (c) Conditions to Vesting 

At the time of the grant of Restricted Stock Units, the Committee may impose such restrictions or conditions to the vesting of such Restricted
Stock Units as it, in its sole discretion, deems appropriate. By way of example and not by way of limitation, the Committee may require, as a condition to the vesting of any class or classes of Restricted Stock Units, that the Participant or the
Company achieves such performance goals as the Committee may specify under Section 12. 
 (d) Dividends on Restricted Stock Units 

The Committee may, in its sole discretion and as would be set forth in the applicable Award Agreement, require each Restricted Stock Unit to
be credited with dividends paid by the Company with respect to one share of Company Stock (“Dividend Equivalents”). Dividend Equivalents shall be withheld by the Company and credited to the Participant’s account, and interest may be
credited on the amount of cash Dividend Equivalents credited to the Participant’s account at a rate and subject to such terms as determined by the Committee in its sole discretion. Dividend Equivalents credited to a Participant’s account
and attributable to any particular Restricted Stock Unit (and earnings thereon, if applicable) shall be distributed in cash or, at the sole discretion of the Committee, in shares of Common Stock having a Fair Market Value equal to the amount of such
Dividend Equivalents and earnings, if applicable, to the Participant upon settlement of such Restricted Stock Unit and, if such Restricted Stock is forfeited, the Participant shall have no right to such Dividend Equivalents. 

(e) Effect of Termination of Employment 

(1) Unless the applicable Award Agreement or the Committee determines otherwise, Restricted Stock Units that have not vested, together with
dividends, if any, credited on such Restricted Stock Units, shall be forfeited upon the Participant’s termination of employment for any reason other than for Cause. 

(2) In the event of the termination of a Participant’s employment for Cause, all Restricted Stock Units granted to such Participant that
have not vested as of the date of such termination shall immediately be forfeited, together with dividends, if any, credited on such shares. 

(f) Effect of Change in Control 

Upon the occurrence of a Change in Control all outstanding Restricted Stock Units that have not theretofore vested shall immediately vest. In
addition, in the event of a Change in Control, the Committee may in its discretion, cancel any outstanding Restricted Stock Units and pay to the holders thereof, in cash or stock, or any combination thereof, the value of such Restricted Stock Units
based upon the price per share of Company Stock to be received by other stockholders of the Company in the Change in Control. 
  

	11	STOCK BONUSES 

 In the event that the Committee grants a Stock Bonus, a
certificate for the shares of Company Stock comprising such Stock Bonus shall be issued in the name of the Participant to whom such grant was made and delivered to such Participant as soon as practicable after the date on which such Stock Bonus is
payable. 

  
 16 

	12	PERFORMANCE-BASED AWARDS 

 (a) Purpose. 

The purpose of this Section 12 is to provide the Committee the ability to qualify Incentive Awards as Qualified Performance-Based
Compensation. If the Committee, in its sole discretion, decides to grant a Performance-Based Award to a Covered Employee, the provisions of this Section 12 shall control over any contrary provision contained in Sections 7, 8, 9 or 10; provided,
however, that the Committee may in its sole discretion grant Incentive Awards to Covered Employees and to other Participants that are based on Performance Criteria or Performance Goals, but that do not satisfy the requirements of this
Section 12. 
 (b) Applicability. 

This Section 12 shall apply only to those Covered Employees selected by the Committee to receive Performance-Based Awards, which are
intended to qualify as Qualified Performance-Based Compensation. The designation of a Covered Employee as a Participant for a Performance Period shall not in any manner entitle the Participant to receive an Incentive Award for the period. Moreover,
designation of a Covered Employee as a Participant for a particular Performance Period shall not require designation of such Covered Employee as a Participant in any subsequent Performance Period and designation of one Covered Employee as a
Participant shall not require designation of any other Covered Employees as Participants in such period or in any other period. 
 (c)
Procedures with Respect to Performance-Based Awards. 
 To the extent necessary to comply with the Qualified Performance-Based Compensation
requirements of Section 162(m)(4)(C) of the Code, with respect to any Incentive Award granted under Sections 7, 8, 9 or 10 that may be granted to one or more Covered Employees, no later than ninety (90) days following the commencement of
any fiscal year in question or any other designated fiscal period or period of service (or such other time as may be required or permitted by Section 162(m) of the Code), the Committee shall, in writing, (a) designate one or more Covered
Employees, (b) select the Performance Criteria applicable to the Performance Period, (c) establish the Performance Goals, and amounts of such Incentive Awards, as applicable, which may be earned for such Performance Period, and
(d) specify the relationship between Performance Criteria and the Performance Goals and the amounts of such Incentive Awards, as applicable, to be earned by each Covered Employee for such Performance Period. Following the completion of each
Performance Period, the Committee shall certify in writing whether the applicable Performance Goals have been achieved for such Performance Period. In determining the amount of an Incentive Award earned by a Covered Employee, the Committee shall
have the right to reduce or eliminate (but not to increase) the amount of Incentive Award payable at a given level of performance to take into account additional factors that the Committee may deem relevant to the assessment of individual or
corporate performance for the Performance Period. 
 (d) Payment of Performance-Based Awards. 

Unless otherwise provided in the applicable Award Agreement, a Participant must be employed by the Company or a Subsidiary on the day a
Performance-Based Award for such Performance Period is paid to the Participant. Furthermore, a Participant shall be eligible to receive payment pursuant to a Performance-Based Award for a Performance Period only if, and to the extent, the
Performance Goals for such period are achieved. 

  
 17 

 (e) Additional Limitations. 

Notwithstanding any other provision of the Plan, any Incentive Award that is granted to a Covered Employee and is intended to constitute
Qualified Performance-Based Compensation shall be subject to any additional limitations set forth in Section 162(m) of the Code (including any amendment to Section 162(m) of the Code) or any regulations or rulings issued thereunder that
are requirements for qualification as qualified performance-based compensation as described in Section 162(m)(4)(C) of the Code, and the Plan shall be deemed amended to the extent necessary to conform to such requirements. 

 

	13	RIGHTS AS A STOCKHOLDER 

 Except as provided in the Plan or an Award Agreement, no
Participant shall be deemed to be the holder of, or have any rights as a stockholder with respect to, any shares of Company Stock covered by or relating to any Incentive Award until the date of issuance of shares of Company Stock relating to such
Incentive Award to such holder of the Incentive Award. 
 Except as otherwise expressly provided in Sections 3(e) or (f) or as
determined by the Committee in its sole discretion, no adjustment to any Incentive Award shall be made as a result of dividends or other rights being issued with respect to Company Stock for which the record date for such dividend or other rights
occurred prior to the date on which the shares of Company Stock relating to such Incentive Award were issued to the holder of such Incentive Award. 
  

	14	SPIN-OFF AWARDS 

 (a) Notwithstanding anything in the Plan to the contrary, the
terms of the Plan will apply to Spin-off Awards only to the extent that such terms are not inconsistent with the Employee Matters Agreement. 

(b) Notwithstanding anything in the Plan to the contrary, the exercise price of a Spin-off Award that is an Option or an SAR may be less than
the Fair Market Value of Company Stock on the date on which such Option or SAR is granted in order to preserve the intrinsic value, in full, of the outstanding Greatbatch equity award prior to the Spin-off. 

(c) For Spin-off Awards granted to Participants who remain active employees, directors or service providers of Greatbatch or any of its
subsidiaries after the Spin-off, the Participant will be deemed to have terminated employment or service, as applicable, for purposes of his or her Spin-off Award when he or she terminates employment with or service to Greatbatch or its
subsidiaries. 
  

	15	DEFERRAL OF AWARDS 

 The Committee may permit or require the deferral of payment
or settlement of any Restricted Stock Unit or Stock Bonus subject to such rules and procedures as it may establish in its sole discretion. Payment or settlement of Options or SARs may not be deferred unless such deferral would not cause the
provisions of Section 409A of the Code to be violated. 
  

	16	RESTRICTION ON TRANSFER OF SHARES 

 The Committee may impose, either in the Award
Agreement or at the time shares of Company Stock are issued in settlement of an Incentive Award, restrictions on the ability of the Participant to sell or transfer such shares of Company Stock. 

  
 18 

	17	NO SPECIAL EMPLOYMENT RIGHTS; NO RIGHT TO INCENTIVE AWARD 

 Nothing contained in
the Plan or any Award Agreement shall confer upon any Participant any right with respect to the continuation of employment with the Company or interfere in any way with the right of the Company, subject to the terms of any separate employment
agreement to the contrary, at any time to terminate such employment or to increase or decrease the compensation of the Participant. 
 No
person shall have any claim or right to receive an Incentive Award hereunder. The Committee’s granting of an Incentive Award to a Participant at any time shall neither require the Committee to grant any other Incentive Award to such Participant
or other person at any time nor preclude the Committee from making subsequent grants to such Participant or any other person. 
  

	18	SECURITIES MATTERS 

 (a) The Company shall be under no obligation to effect the
registration pursuant to the Securities Act of 1933, as amended, of any interests in the Plan or any shares of Company Stock to be issued hereunder or to effect similar compliance under any state laws. Notwithstanding anything herein to the
contrary, the Company shall not be obligated to cause to be issued or delivered any certificates evidencing shares of Company Stock pursuant to the Plan unless and until the Company is advised by its counsel that the issuance and delivery of such
certificates is in compliance with all applicable laws, regulations of governmental authority and the requirements of the NASDAQ Stock Market or any other securities exchange or automated quotation system on which shares of Company Stock are listed.
Certificates evidencing shares of Company Stock issued pursuant to the terms hereof, may bear such legends, as the Committee or the Company, in its sole discretion, deems necessary or desirable to insure compliance with applicable securities laws.

 (b) The transfer of any shares of Company Stock hereunder shall be effective only at such time as counsel to the Company shall have
determined that the issuance and delivery of such shares is in compliance with all applicable laws, regulations of governmental authority and the requirements of the NASDAQ Stock Market or any other securities exchange or automated quotation system
on which shares of Company Stock are listed. The Committee may, in its sole discretion, defer the effectiveness of any transfer of shares of Company stock hereunder in order to allow the issuance of such shares to be made pursuant to registration or
an exemption from registration or other methods for compliance available under federal or state securities laws. The Company shall inform the Participant in writing of the Committee’s decision to defer the effectiveness of a transfer. During
the period of such a deferral in connection with the exercise of an Option, the Participant may, by written notice, withdraw such exercise and obtain the refund of any amount paid with respect thereto. 

(c) It is intended that the Plan be applied and administered in compliance with Rule 16b-3. If any provision of the Plan would be in violation
of Rule 16b-3 if applied as written, such provision shall not have effect as written and shall be given effect so as to comply with Rule 16b-3, as determined by the Committee. The Committee is authorized to amend the Plan and to make any such
modifications to Award Agreements to comply with Rule 16b-3, as it may be amended from time to time, and to make any other such amendments or modifications deemed necessary or appropriate to better accomplish the purposes of the Plan in light of any
amendments made to Rule 16b-3. 
  

	19	WITHHOLDING TAXES 

 Whenever cash is to be paid pursuant to an Incentive Award,
the Company shall have the right to deduct therefrom an amount sufficient to satisfy any federal, state and local withholding tax requirements related thereto. 

  
 19 

 Whenever shares of Company Stock are to be delivered pursuant to an Incentive Award, the Company
shall have the right to require the Participant to remit to the Company in cash an amount sufficient to satisfy any federal, state and local withholding tax requirements related thereto. With the approval of the Committee, which it shall have sole
discretion to grant and which approval may be evidenced by the presence in the Award Agreement of an appropriate reference to such right, a Participant may satisfy the foregoing requirement by electing to have the Company withhold from delivery
shares of Company Stock having a value equal to the minimum amount of tax required to be withheld. Such shares shall be valued at their Fair Market Value on the date as of which the amount of tax to be withheld is determined. Any fractional share
amounts shall be settled in cash. Such a withholding election may be made with respect to all or any portion of the shares of Company Stock to be delivered pursuant to an Incentive Award. Any tax withholding above the minimum amount of tax required
to be withheld must be deducted from other amounts payable to the Participant or must be paid in cash by the Participant. 
  

	20	NOTIFICATION OF ELECTION UNDER SECTION 83(b) OF THE CODE 

 If any Participant
shall, in connection with the acquisition of shares of Company Stock under the Plan, make the election permitted under Section 83(b) of the Code (i.e., an election to include in gross income in the year of transfer the amounts specified in
Section 83(b) of the Code) and permitted under the terms of the Award Agreement, such Participant shall notify the Company of such election within ten days of filing notice of the election with the Internal Revenue Service, in addition to any
filing and notification required pursuant to regulations issued under the authority of Code Section 83(b). 
  

	21	NOTIFICATION UPON DISQUALIFYING DISPOSITION UNDER SECTION 421(b) OF THE CODE 

Each Award Agreement with respect to an Incentive Stock Option shall require the Participant to notify the Company of any disposition of shares
of Company Stock issued pursuant to the exercise of such Incentive Stock Option under the circumstances described in Section 421(b) of the Code (relating to certain disqualifying dispositions) within ten (10) days of such disposition. 

 

	22	AMENDMENT OR TERMINATION OF THE PLAN 

 The Board of Directors may, at any time,
suspend or terminate the Plan or revise or amend it in any respect whatsoever; provided, however, that stockholder approval shall be required if and to the extent required by Rule 16b-3 or by any comparable or successor exemption under which the
Board of Directors believes it is appropriate for the Plan to qualify, or if and to the extent the Board of Directors determines that such approval is appropriate for purposes of satisfying Section 162(m), Section 422 or Section 409A
of the Code or any applicable rule or listing standard of any stock exchange, automated quotation system or similar organization. Nothing herein shall restrict the Committee’s ability to exercise its discretionary authority pursuant to
Section 4, which discretion may be exercised without amendment to the Plan. No action hereunder may, without the consent of a Participant, reduce the Participant’s rights under any outstanding Incentive Award. 

 

	23	NO OBLIGATION TO EXERCISE 

 The grant to a Participant of an Option or SAR shall
impose no obligation upon such Participant to exercise such Option or SAR. 

  
 20 

	24	TRANSFERS UPON DEATH; NONASSIGNABILITY 

 Upon the death of a Participant
outstanding Incentive Awards granted to such Participant may be exercised only by the executor or administrator of the Participant’s estate or by a person who shall have acquired the right to such exercise by will or by the laws of descent and
distribution. No transfer of an Incentive Award by will or the laws of descent and distribution shall be effective to bind the Company unless the Company shall have been furnished with (a) written notice thereof and with a copy of the will
and/or such evidence as the Committee may deem necessary to establish the validity of the transfer and (b) an agreement by the transferee to comply with all the terms and conditions of the Incentive Award that are or would have been applicable
to the Participant and to be bound by the acknowledgments made by the Participant in connection with the grant of the Incentive Award. 

Except as otherwise provided in this Plan, no Incentive Award or interest in it may be transferred, assigned, pledged or hypothecated by the
Participant, whether by operation of law or otherwise, or be made subject to execution, attachment or similar process. 
  

	25	EXPENSES AND RECEIPTS 

 The expenses of the Plan shall be paid by the Company. Any
proceeds received by the Company in connection with any Incentive Award will be used for general corporate purposes. 
  

	26	FAILURE TO COMPLY 

 In addition to the remedies of the Company elsewhere provided
for herein, failure by a Participant (or beneficiary) to comply with any of the terms and conditions of the Plan or the applicable Award Agreement, unless such failure is remedied by such Participant (or beneficiary) within ten (10) days after
notice of such failure by the Committee, shall be grounds for the cancellation and forfeiture of such Incentive Award, in whole or in part, as the Committee, in its sole discretion, may determine. 

 

	27	EFFECTIVE DATE AND TERM OF PLAN 

 The Plan shall be effective as of the Effective
Date. Unless earlier terminated by the Board of Directors, the right to grant Incentive Awards under the Plan will terminate on the tenth (10th) anniversary of the Effective Date. Incentive
Awards outstanding at Plan termination will remain in effect according to their terms and the provisions of the Plan. 
  

	28	FRACTIONAL SHARES 

 No fractional shares of Company Stock shall be issued or
delivered pursuant to the Plan. The Committee shall determine whether cash or other securities or property shall be issued or paid in lieu of fractional shares of Company Stock or whether any fractional shares should be rounded, forfeited or
otherwise eliminated. 
  

	29	CLAWBACK 

 Any Incentive Award that is subject to recovery under any applicable
law, government regulation or rule or listing standard of any stock exchange, will be subject to such deductions and clawback as may be required to be made pursuant to such applicable law, government regulation or rule or listing standard of any
stock exchange (or any policy adopted by the Company pursuant to any such applicable law, government regulation or rule or listing standard of any stock exchange). 

  
 21 

	30	SEVERABILITY 

 If any of the provisions of the Plan or any Award Agreement is held
to be invalid, illegal or unenforceable, whether in whole or in part, such provision shall be deemed modified to the extent, but only to the extent, of such invalidity, illegality or unenforceability and the remaining provisions shall not be
affected thereby. 
  

	31	AWARDS TO NON-U.S. EMPLOYEES 

 Incentive Awards may be granted to Participants who
are foreign nationals or employed outside of the United States, or both, on such terms and conditions different from those applicable to Incentive Awards to Participants employed in the United States as may, in the judgement of the Committee, be
necessary or desirable in order to recognize differences in local law or tax policy. The Committee may impose conditions on the exercise or vesting in Incentive Awards in order to minimize the Company’s obligations with respect to tax
equalization for employees on assignment outside of their home country. 
  

	32	SECTION 409A 

 All Incentive Awards granted under this Plan are intended to comply
with or to be exempt from Section 409A of the Code and will be construed accordingly. However, the Company will not be liable to any Participant or beneficiary with respect to any adverse tax consequences arising under Section 409A or
other provision of the Code. All terms of this Plan that are undefined or ambiguous must be interpreted in a manner that is consistent with Section 409A of the Code if necessary to comply with Section 409A of the Code. A Participant’s
right to receive any installment payments under this Plan or an Incentive Award Agreement will be treated as a right to receive a series of separate payments for purposes of Section 409A of the Code. To the extent that (i) a Participant is
determined to be a “specified employee” within the meaning of Section 409A of the Code, (b) any amounts payable under this Plan or an Award Agreement represent amounts that are subject to Section 409A of the Code, and
(c) such amounts are payable solely on the Participant’s “separation from service” within the meaning of Section 409A of the Code, then such amounts will not be payable to the Participant before the date that is six months
after the Participant’s separation from service (or, if earlier, the date of the Participant’s death), to the extent necessary to avoid the imposition of tax penalties on the Participant under Section 409A of the Code. Payments
subject to the preceding sentence to which the Participant would otherwise be entitled during the first six months following the Participant’s separation date will be accumulated and paid on the first business day that is six months after the
separation date. 
  

	33	APPLICABLE LAW 

 Except to the extent preempted by any applicable federal law, the
Plan will be construed and administered in accordance with the laws of the State of Delaware, without reference to the principles of conflicts of laws thereunder. 

  
 22

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}]]